nct_id,brief_title,official_title,study_type,phase,enrollment,start_date,completion_date,overall_status,lead_sponsor,study_design,primary_purpose,antibody_name,antibody_category,indication
NCT36359049,Study of Rituximab in Lymphoma,A Phase 1 Study of Rituximab for the Treatment of Lymphoma,Interventional,Phase 1,245,2024-07-06,2026-03-10,Suspended,Industry,Crossover Assignment,Prevention,Rituximab,Anti-CD20,Lymphoma
NCT48729418,Study of Rituximab in Lymphoma,A Phase 1 Study of Rituximab for the Treatment of Lymphoma,Interventional,Phase 1,865,2024-01-19,2024-08-18,Recruiting,NIH,Single Group Assignment,Supportive Care,Rituximab,Anti-CD20,Lymphoma
NCT32734633,Study of Rituximab in Lymphoma,A Phase 1 Study of Rituximab for the Treatment of Lymphoma,Observational,Phase 1,673,2023-01-15,2023-06-29,Completed,Industry,Single Group Assignment,Supportive Care,Rituximab,Anti-CD20,Lymphoma
NCT57871801,Study of Rituximab in Lymphoma,A Phase 2 Study of Rituximab for the Treatment of Lymphoma,Interventional,Phase 2,310,2023-09-10,2023-12-19,Suspended,NIH,Single Group Assignment,Supportive Care,Rituximab,Anti-CD20,Lymphoma
NCT83581942,Study of Rituximab in Lymphoma,A Phase 2 Study of Rituximab for the Treatment of Lymphoma,Observational,Phase 2,72,2023-12-17,2025-11-17,Terminated,NIH,Parallel Assignment,Treatment,Rituximab,Anti-CD20,Lymphoma
NCT23823136,Study of Rituximab in Lymphoma,A Phase 3 Study of Rituximab for the Treatment of Lymphoma,Interventional,Phase 3,230,2024-06-16,2025-06-28,Recruiting,NIH,Parallel Assignment,Prevention,Rituximab,Anti-CD20,Lymphoma
NCT93654326,Study of Rituximab in Lymphoma,A Phase 3 Study of Rituximab for the Treatment of Lymphoma,Interventional,Phase 3,412,2023-10-14,2025-08-15,Terminated,Other,Crossover Assignment,Supportive Care,Rituximab,Anti-CD20,Lymphoma
NCT64586623,Study of Rituximab in Lymphoma,A Phase 3 Study of Rituximab for the Treatment of Lymphoma,Observational,Phase 3,396,2021-11-16,2023-05-13,Terminated,NIH,Crossover Assignment,Treatment,Rituximab,Anti-CD20,Lymphoma
NCT17057020,Study of Rituximab in Lymphoma,A Phase 4 Study of Rituximab for the Treatment of Lymphoma,Observational,Phase 4,639,2021-07-26,2023-03-31,Terminated,Industry,Crossover Assignment,Diagnostic,Rituximab,Anti-CD20,Lymphoma
NCT44586030,Study of Rituximab in Lymphoma,A Phase 4 Study of Rituximab for the Treatment of Lymphoma,Observational,Phase 4,206,2024-04-24,2025-08-01,Suspended,NIH,Crossover Assignment,Supportive Care,Rituximab,Anti-CD20,Lymphoma
NCT67064918,Study of Rituximab in Lymphoma,A Phase 4 Study of Rituximab for the Treatment of Lymphoma,Interventional,Phase 4,812,2021-08-13,2022-05-01,Suspended,Industry,Parallel Assignment,Supportive Care,Rituximab,Anti-CD20,Lymphoma
NCT98784408,Study of Rituximab in Leukemia,A Phase 1 Study of Rituximab for the Treatment of Leukemia,Observational,Phase 1,907,2020-12-10,2021-01-10,Terminated,Other,Single Group Assignment,Prevention,Rituximab,Anti-CD20,Leukemia
NCT16782352,Study of Rituximab in Leukemia,A Phase 1 Study of Rituximab for the Treatment of Leukemia,Interventional,Phase 1,777,2024-02-20,2025-12-27,Suspended,Industry,Crossover Assignment,Supportive Care,Rituximab,Anti-CD20,Leukemia
NCT85076861,Study of Rituximab in Leukemia,A Phase 1 Study of Rituximab for the Treatment of Leukemia,Observational,Phase 1,870,2020-06-19,2020-10-10,Recruiting,Industry,Crossover Assignment,Diagnostic,Rituximab,Anti-CD20,Leukemia
NCT82030671,Study of Rituximab in Leukemia,A Phase 2 Study of Rituximab for the Treatment of Leukemia,Interventional,Phase 2,579,2024-02-08,2025-04-09,Terminated,Industry,Parallel Assignment,Treatment,Rituximab,Anti-CD20,Leukemia
NCT68989080,Study of Rituximab in Leukemia,A Phase 3 Study of Rituximab for the Treatment of Leukemia,Interventional,Phase 3,646,2022-01-17,2024-01-14,Suspended,NIH,Single Group Assignment,Supportive Care,Rituximab,Anti-CD20,Leukemia
NCT69137751,Study of Rituximab in Leukemia,A Phase 3 Study of Rituximab for the Treatment of Leukemia,Interventional,Phase 3,983,2023-09-09,2025-09-04,Completed,Industry,Single Group Assignment,Diagnostic,Rituximab,Anti-CD20,Leukemia
NCT48835969,Study of Rituximab in Leukemia,A Phase 4 Study of Rituximab for the Treatment of Leukemia,Interventional,Phase 4,766,2020-08-11,2022-08-01,Recruiting,Industry,Single Group Assignment,Treatment,Rituximab,Anti-CD20,Leukemia
NCT59816313,Study of Rituximab in Leukemia,A Phase 4 Study of Rituximab for the Treatment of Leukemia,Observational,Phase 4,526,2022-01-25,2022-10-01,Recruiting,Other,Crossover Assignment,Supportive Care,Rituximab,Anti-CD20,Leukemia
NCT57743063,Study of Rituximab in Leukemia,A Phase 4 Study of Rituximab for the Treatment of Leukemia,Observational,Phase 4,149,2022-08-07,2023-08-13,Suspended,Industry,Crossover Assignment,Supportive Care,Rituximab,Anti-CD20,Leukemia
NCT91513091,Study of Rituximab in Multiple Sclerosis,A Phase 1 Study of Rituximab for the Treatment of Multiple Sclerosis,Interventional,Phase 1,480,2020-08-27,2021-10-20,Recruiting,Other,Single Group Assignment,Supportive Care,Rituximab,Anti-CD20,Multiple Sclerosis
NCT24762298,Study of Rituximab in Multiple Sclerosis,A Phase 1 Study of Rituximab for the Treatment of Multiple Sclerosis,Interventional,Phase 1,390,2020-04-15,2022-03-10,Completed,NIH,Crossover Assignment,Supportive Care,Rituximab,Anti-CD20,Multiple Sclerosis
NCT29922611,Study of Rituximab in Multiple Sclerosis,A Phase 2 Study of Rituximab for the Treatment of Multiple Sclerosis,Observational,Phase 2,288,2020-10-02,2022-04-12,Terminated,Other,Single Group Assignment,Diagnostic,Rituximab,Anti-CD20,Multiple Sclerosis
NCT70687198,Study of Rituximab in Multiple Sclerosis,A Phase 2 Study of Rituximab for the Treatment of Multiple Sclerosis,Interventional,Phase 2,970,2022-07-03,2023-01-16,Completed,Industry,Crossover Assignment,Supportive Care,Rituximab,Anti-CD20,Multiple Sclerosis
NCT65627719,Study of Rituximab in Multiple Sclerosis,A Phase 3 Study of Rituximab for the Treatment of Multiple Sclerosis,Interventional,Phase 3,36,2024-01-06,2026-01-01,Suspended,NIH,Crossover Assignment,Treatment,Rituximab,Anti-CD20,Multiple Sclerosis
NCT39275439,Study of Rituximab in Multiple Sclerosis,A Phase 3 Study of Rituximab for the Treatment of Multiple Sclerosis,Interventional,Phase 3,525,2021-06-25,2023-06-02,Terminated,Industry,Single Group Assignment,Prevention,Rituximab,Anti-CD20,Multiple Sclerosis
NCT13086082,Study of Rituximab in Multiple Sclerosis,A Phase 4 Study of Rituximab for the Treatment of Multiple Sclerosis,Observational,Phase 4,196,2022-09-10,2023-01-17,Terminated,NIH,Crossover Assignment,Treatment,Rituximab,Anti-CD20,Multiple Sclerosis
NCT16210378,Study of Rituximab in Multiple Sclerosis,A Phase 4 Study of Rituximab for the Treatment of Multiple Sclerosis,Interventional,Phase 4,911,2023-01-10,2024-09-30,Completed,Other,Crossover Assignment,Supportive Care,Rituximab,Anti-CD20,Multiple Sclerosis
NCT24962589,Study of Obinutuzumab in Lymphoma,A Phase 1 Study of Obinutuzumab for the Treatment of Lymphoma,Interventional,Phase 1,88,2022-04-14,2022-09-16,Suspended,Industry,Crossover Assignment,Diagnostic,Obinutuzumab,Anti-CD20,Lymphoma
NCT32126806,Study of Obinutuzumab in Lymphoma,A Phase 2 Study of Obinutuzumab for the Treatment of Lymphoma,Observational,Phase 2,74,2022-05-03,2023-08-04,Terminated,NIH,Crossover Assignment,Diagnostic,Obinutuzumab,Anti-CD20,Lymphoma
NCT40778145,Study of Obinutuzumab in Lymphoma,A Phase 2 Study of Obinutuzumab for the Treatment of Lymphoma,Interventional,Phase 2,514,2022-04-13,2022-08-09,Completed,Industry,Single Group Assignment,Supportive Care,Obinutuzumab,Anti-CD20,Lymphoma
NCT27960108,Study of Obinutuzumab in Lymphoma,A Phase 3 Study of Obinutuzumab for the Treatment of Lymphoma,Observational,Phase 3,340,2020-08-10,2021-10-25,Suspended,Industry,Parallel Assignment,Prevention,Obinutuzumab,Anti-CD20,Lymphoma
NCT18105917,Study of Obinutuzumab in Lymphoma,A Phase 3 Study of Obinutuzumab for the Treatment of Lymphoma,Observational,Phase 3,783,2021-09-16,2021-11-03,Recruiting,NIH,Single Group Assignment,Prevention,Obinutuzumab,Anti-CD20,Lymphoma
NCT47616921,Study of Obinutuzumab in Lymphoma,A Phase 4 Study of Obinutuzumab for the Treatment of Lymphoma,Interventional,Phase 4,346,2024-12-05,2025-10-31,Suspended,NIH,Single Group Assignment,Diagnostic,Obinutuzumab,Anti-CD20,Lymphoma
NCT63782469,Study of Obinutuzumab in Leukemia,A Phase 1 Study of Obinutuzumab for the Treatment of Leukemia,Observational,Phase 1,620,2022-07-01,2023-11-11,Terminated,NIH,Crossover Assignment,Treatment,Obinutuzumab,Anti-CD20,Leukemia
NCT20258271,Study of Obinutuzumab in Leukemia,A Phase 1 Study of Obinutuzumab for the Treatment of Leukemia,Interventional,Phase 1,900,2023-08-22,2024-07-09,Terminated,NIH,Parallel Assignment,Supportive Care,Obinutuzumab,Anti-CD20,Leukemia
NCT94625568,Study of Obinutuzumab in Leukemia,A Phase 2 Study of Obinutuzumab for the Treatment of Leukemia,Observational,Phase 2,160,2024-03-05,2025-05-05,Terminated,NIH,Single Group Assignment,Supportive Care,Obinutuzumab,Anti-CD20,Leukemia
NCT51289540,Study of Obinutuzumab in Leukemia,A Phase 3 Study of Obinutuzumab for the Treatment of Leukemia,Observational,Phase 3,236,2023-02-17,2023-11-04,Terminated,NIH,Single Group Assignment,Treatment,Obinutuzumab,Anti-CD20,Leukemia
NCT45429745,Study of Obinutuzumab in Leukemia,A Phase 4 Study of Obinutuzumab for the Treatment of Leukemia,Observational,Phase 4,788,2021-05-10,2021-11-10,Terminated,Other,Parallel Assignment,Prevention,Obinutuzumab,Anti-CD20,Leukemia
NCT15896378,Study of Obinutuzumab in Leukemia,A Phase 4 Study of Obinutuzumab for the Treatment of Leukemia,Observational,Phase 4,428,2023-03-16,2025-02-08,Terminated,NIH,Parallel Assignment,Supportive Care,Obinutuzumab,Anti-CD20,Leukemia
NCT93671633,Study of Obinutuzumab in Multiple Sclerosis,A Phase 1 Study of Obinutuzumab for the Treatment of Multiple Sclerosis,Interventional,Phase 1,684,2022-08-01,2024-01-23,Terminated,Other,Single Group Assignment,Treatment,Obinutuzumab,Anti-CD20,Multiple Sclerosis
NCT93467774,Study of Obinutuzumab in Multiple Sclerosis,A Phase 1 Study of Obinutuzumab for the Treatment of Multiple Sclerosis,Interventional,Phase 1,735,2020-11-22,2022-03-12,Suspended,Industry,Parallel Assignment,Prevention,Obinutuzumab,Anti-CD20,Multiple Sclerosis
NCT93947495,Study of Obinutuzumab in Multiple Sclerosis,A Phase 1 Study of Obinutuzumab for the Treatment of Multiple Sclerosis,Observational,Phase 1,92,2020-08-28,2021-08-07,Terminated,Industry,Crossover Assignment,Treatment,Obinutuzumab,Anti-CD20,Multiple Sclerosis
NCT21889641,Study of Obinutuzumab in Multiple Sclerosis,A Phase 2 Study of Obinutuzumab for the Treatment of Multiple Sclerosis,Interventional,Phase 2,722,2021-04-29,2022-08-03,Terminated,Other,Single Group Assignment,Prevention,Obinutuzumab,Anti-CD20,Multiple Sclerosis
NCT32396804,Study of Obinutuzumab in Multiple Sclerosis,A Phase 2 Study of Obinutuzumab for the Treatment of Multiple Sclerosis,Observational,Phase 2,73,2024-01-31,2025-06-21,Completed,Industry,Parallel Assignment,Diagnostic,Obinutuzumab,Anti-CD20,Multiple Sclerosis
NCT99144820,Study of Obinutuzumab in Multiple Sclerosis,A Phase 3 Study of Obinutuzumab for the Treatment of Multiple Sclerosis,Observational,Phase 3,410,2020-08-01,2021-08-15,Completed,Industry,Single Group Assignment,Diagnostic,Obinutuzumab,Anti-CD20,Multiple Sclerosis
NCT23459864,Study of Obinutuzumab in Multiple Sclerosis,A Phase 4 Study of Obinutuzumab for the Treatment of Multiple Sclerosis,Observational,Phase 4,355,2025-01-13,2025-05-02,Suspended,Industry,Crossover Assignment,Diagnostic,Obinutuzumab,Anti-CD20,Multiple Sclerosis
NCT29029783,Study of Obinutuzumab in Multiple Sclerosis,A Phase 4 Study of Obinutuzumab for the Treatment of Multiple Sclerosis,Interventional,Phase 4,977,2021-06-17,2022-11-26,Completed,Industry,Single Group Assignment,Treatment,Obinutuzumab,Anti-CD20,Multiple Sclerosis
NCT84463325,Study of Obinutuzumab in Multiple Sclerosis,A Phase 4 Study of Obinutuzumab for the Treatment of Multiple Sclerosis,Observational,Phase 4,543,2023-02-01,2023-08-20,Completed,Industry,Single Group Assignment,Prevention,Obinutuzumab,Anti-CD20,Multiple Sclerosis
NCT27329313,Study of Ofatumumab in Lymphoma,A Phase 1 Study of Ofatumumab for the Treatment of Lymphoma,Interventional,Phase 1,693,2020-12-26,2022-04-10,Terminated,NIH,Single Group Assignment,Treatment,Ofatumumab,Anti-CD20,Lymphoma
NCT37540896,Study of Ofatumumab in Lymphoma,A Phase 2 Study of Ofatumumab for the Treatment of Lymphoma,Observational,Phase 2,351,2021-11-11,2022-12-04,Completed,NIH,Single Group Assignment,Treatment,Ofatumumab,Anti-CD20,Lymphoma
NCT89973394,Study of Ofatumumab in Lymphoma,A Phase 2 Study of Ofatumumab for the Treatment of Lymphoma,Interventional,Phase 2,466,2024-02-16,2025-10-30,Suspended,NIH,Crossover Assignment,Treatment,Ofatumumab,Anti-CD20,Lymphoma
NCT77548914,Study of Ofatumumab in Lymphoma,A Phase 3 Study of Ofatumumab for the Treatment of Lymphoma,Observational,Phase 3,295,2023-07-25,2024-02-29,Recruiting,Other,Single Group Assignment,Prevention,Ofatumumab,Anti-CD20,Lymphoma
NCT64988149,Study of Ofatumumab in Lymphoma,A Phase 4 Study of Ofatumumab for the Treatment of Lymphoma,Observational,Phase 4,692,2022-08-08,2023-07-27,Completed,NIH,Parallel Assignment,Prevention,Ofatumumab,Anti-CD20,Lymphoma
NCT69249820,Study of Ofatumumab in Lymphoma,A Phase 4 Study of Ofatumumab for the Treatment of Lymphoma,Interventional,Phase 4,459,2023-06-27,2024-04-16,Completed,NIH,Single Group Assignment,Supportive Care,Ofatumumab,Anti-CD20,Lymphoma
NCT78462301,Study of Ofatumumab in Lymphoma,A Phase 4 Study of Ofatumumab for the Treatment of Lymphoma,Interventional,Phase 4,379,2020-04-12,2020-09-19,Suspended,Other,Crossover Assignment,Diagnostic,Ofatumumab,Anti-CD20,Lymphoma
NCT98305573,Study of Ofatumumab in Leukemia,A Phase 1 Study of Ofatumumab for the Treatment of Leukemia,Observational,Phase 1,642,2022-01-02,2023-12-29,Suspended,NIH,Parallel Assignment,Supportive Care,Ofatumumab,Anti-CD20,Leukemia
NCT25684850,Study of Ofatumumab in Leukemia,A Phase 1 Study of Ofatumumab for the Treatment of Leukemia,Interventional,Phase 1,474,2022-06-05,2023-12-17,Terminated,Industry,Parallel Assignment,Treatment,Ofatumumab,Anti-CD20,Leukemia
NCT35402693,Study of Ofatumumab in Leukemia,A Phase 1 Study of Ofatumumab for the Treatment of Leukemia,Observational,Phase 1,364,2021-09-16,2023-07-13,Recruiting,Industry,Parallel Assignment,Supportive Care,Ofatumumab,Anti-CD20,Leukemia
NCT10712776,Study of Ofatumumab in Leukemia,A Phase 2 Study of Ofatumumab for the Treatment of Leukemia,Interventional,Phase 2,215,2023-10-22,2025-10-21,Recruiting,Other,Crossover Assignment,Prevention,Ofatumumab,Anti-CD20,Leukemia
NCT25015027,Study of Ofatumumab in Leukemia,A Phase 2 Study of Ofatumumab for the Treatment of Leukemia,Interventional,Phase 2,267,2023-10-21,2024-07-31,Terminated,Industry,Parallel Assignment,Treatment,Ofatumumab,Anti-CD20,Leukemia
NCT11694638,Study of Ofatumumab in Leukemia,A Phase 3 Study of Ofatumumab for the Treatment of Leukemia,Interventional,Phase 3,658,2024-06-04,2025-09-14,Terminated,Other,Parallel Assignment,Prevention,Ofatumumab,Anti-CD20,Leukemia
NCT76832648,Study of Ofatumumab in Leukemia,A Phase 3 Study of Ofatumumab for the Treatment of Leukemia,Observational,Phase 3,609,2021-01-26,2022-06-14,Terminated,NIH,Crossover Assignment,Supportive Care,Ofatumumab,Anti-CD20,Leukemia
NCT35783129,Study of Ofatumumab in Leukemia,A Phase 3 Study of Ofatumumab for the Treatment of Leukemia,Interventional,Phase 3,939,2023-07-07,2023-12-20,Terminated,NIH,Single Group Assignment,Prevention,Ofatumumab,Anti-CD20,Leukemia
NCT36392133,Study of Ofatumumab in Leukemia,A Phase 4 Study of Ofatumumab for the Treatment of Leukemia,Observational,Phase 4,976,2023-01-20,2024-02-18,Suspended,Other,Single Group Assignment,Diagnostic,Ofatumumab,Anti-CD20,Leukemia
NCT49566743,Study of Ofatumumab in Leukemia,A Phase 4 Study of Ofatumumab for the Treatment of Leukemia,Interventional,Phase 4,342,2022-04-19,2024-01-20,Recruiting,Other,Crossover Assignment,Prevention,Ofatumumab,Anti-CD20,Leukemia
NCT66807541,Study of Ofatumumab in Leukemia,A Phase 4 Study of Ofatumumab for the Treatment of Leukemia,Observational,Phase 4,498,2020-08-31,2021-05-07,Terminated,NIH,Crossover Assignment,Diagnostic,Ofatumumab,Anti-CD20,Leukemia
NCT17616731,Study of Ofatumumab in Multiple Sclerosis,A Phase 1 Study of Ofatumumab for the Treatment of Multiple Sclerosis,Observational,Phase 1,463,2022-07-14,2023-07-27,Terminated,Other,Parallel Assignment,Diagnostic,Ofatumumab,Anti-CD20,Multiple Sclerosis
NCT15397926,Study of Ofatumumab in Multiple Sclerosis,A Phase 2 Study of Ofatumumab for the Treatment of Multiple Sclerosis,Interventional,Phase 2,96,2024-12-16,2026-02-05,Recruiting,NIH,Parallel Assignment,Supportive Care,Ofatumumab,Anti-CD20,Multiple Sclerosis
NCT97402885,Study of Ofatumumab in Multiple Sclerosis,A Phase 2 Study of Ofatumumab for the Treatment of Multiple Sclerosis,Observational,Phase 2,569,2022-03-10,2024-02-20,Completed,Other,Single Group Assignment,Diagnostic,Ofatumumab,Anti-CD20,Multiple Sclerosis
NCT86890998,Study of Ofatumumab in Multiple Sclerosis,A Phase 3 Study of Ofatumumab for the Treatment of Multiple Sclerosis,Interventional,Phase 3,291,2021-01-22,2022-02-24,Suspended,Other,Parallel Assignment,Supportive Care,Ofatumumab,Anti-CD20,Multiple Sclerosis
NCT13167781,Study of Ofatumumab in Multiple Sclerosis,A Phase 3 Study of Ofatumumab for the Treatment of Multiple Sclerosis,Observational,Phase 3,986,2021-10-20,2023-05-20,Terminated,NIH,Parallel Assignment,Supportive Care,Ofatumumab,Anti-CD20,Multiple Sclerosis
NCT76528896,Study of Ofatumumab in Multiple Sclerosis,A Phase 4 Study of Ofatumumab for the Treatment of Multiple Sclerosis,Observational,Phase 4,155,2025-03-23,2026-03-22,Completed,NIH,Crossover Assignment,Diagnostic,Ofatumumab,Anti-CD20,Multiple Sclerosis
NCT63286949,Study of Ofatumumab in Multiple Sclerosis,A Phase 4 Study of Ofatumumab for the Treatment of Multiple Sclerosis,Observational,Phase 4,869,2024-04-11,2024-06-25,Completed,Other,Crossover Assignment,Treatment,Ofatumumab,Anti-CD20,Multiple Sclerosis
NCT86109948,Study of Ocrelizumab in Lymphoma,A Phase 1 Study of Ocrelizumab for the Treatment of Lymphoma,Interventional,Phase 1,985,2023-07-29,2023-10-17,Recruiting,Other,Single Group Assignment,Prevention,Ocrelizumab,Anti-CD20,Lymphoma
NCT86915742,Study of Ocrelizumab in Lymphoma,A Phase 2 Study of Ocrelizumab for the Treatment of Lymphoma,Interventional,Phase 2,41,2021-03-17,2023-01-26,Recruiting,Industry,Single Group Assignment,Diagnostic,Ocrelizumab,Anti-CD20,Lymphoma
NCT41400974,Study of Ocrelizumab in Lymphoma,A Phase 2 Study of Ocrelizumab for the Treatment of Lymphoma,Interventional,Phase 2,158,2021-02-26,2021-05-30,Suspended,Other,Parallel Assignment,Diagnostic,Ocrelizumab,Anti-CD20,Lymphoma
NCT57661992,Study of Ocrelizumab in Lymphoma,A Phase 3 Study of Ocrelizumab for the Treatment of Lymphoma,Observational,Phase 3,112,2021-07-06,2021-12-11,Recruiting,Industry,Single Group Assignment,Diagnostic,Ocrelizumab,Anti-CD20,Lymphoma
NCT39141575,Study of Ocrelizumab in Lymphoma,A Phase 4 Study of Ocrelizumab for the Treatment of Lymphoma,Interventional,Phase 4,118,2023-05-18,2025-02-20,Suspended,Industry,Single Group Assignment,Prevention,Ocrelizumab,Anti-CD20,Lymphoma
NCT73360696,Study of Ocrelizumab in Leukemia,A Phase 1 Study of Ocrelizumab for the Treatment of Leukemia,Observational,Phase 1,617,2020-11-20,2021-02-07,Recruiting,NIH,Single Group Assignment,Prevention,Ocrelizumab,Anti-CD20,Leukemia
NCT72416710,Study of Ocrelizumab in Leukemia,A Phase 1 Study of Ocrelizumab for the Treatment of Leukemia,Observational,Phase 1,559,2022-11-15,2023-05-11,Completed,Other,Crossover Assignment,Supportive Care,Ocrelizumab,Anti-CD20,Leukemia
NCT42921792,Study of Ocrelizumab in Leukemia,A Phase 1 Study of Ocrelizumab for the Treatment of Leukemia,Interventional,Phase 1,758,2021-02-09,2021-12-04,Suspended,Other,Crossover Assignment,Supportive Care,Ocrelizumab,Anti-CD20,Leukemia
NCT67285403,Study of Ocrelizumab in Leukemia,A Phase 2 Study of Ocrelizumab for the Treatment of Leukemia,Interventional,Phase 2,949,2024-11-12,2025-12-18,Recruiting,Other,Single Group Assignment,Treatment,Ocrelizumab,Anti-CD20,Leukemia
NCT16510682,Study of Ocrelizumab in Leukemia,A Phase 2 Study of Ocrelizumab for the Treatment of Leukemia,Interventional,Phase 2,888,2023-09-23,2025-06-19,Terminated,Other,Single Group Assignment,Supportive Care,Ocrelizumab,Anti-CD20,Leukemia
NCT62742948,Study of Ocrelizumab in Leukemia,A Phase 2 Study of Ocrelizumab for the Treatment of Leukemia,Interventional,Phase 2,653,2022-06-15,2023-03-31,Recruiting,Industry,Parallel Assignment,Supportive Care,Ocrelizumab,Anti-CD20,Leukemia
NCT99184747,Study of Ocrelizumab in Leukemia,A Phase 3 Study of Ocrelizumab for the Treatment of Leukemia,Interventional,Phase 3,573,2020-04-10,2021-07-12,Recruiting,NIH,Parallel Assignment,Supportive Care,Ocrelizumab,Anti-CD20,Leukemia
NCT33886240,Study of Ocrelizumab in Leukemia,A Phase 3 Study of Ocrelizumab for the Treatment of Leukemia,Observational,Phase 3,53,2025-05-10,2025-10-07,Recruiting,Other,Crossover Assignment,Supportive Care,Ocrelizumab,Anti-CD20,Leukemia
NCT89092666,Study of Ocrelizumab in Leukemia,A Phase 3 Study of Ocrelizumab for the Treatment of Leukemia,Observational,Phase 3,563,2024-06-27,2024-09-29,Suspended,NIH,Single Group Assignment,Prevention,Ocrelizumab,Anti-CD20,Leukemia
NCT58611678,Study of Ocrelizumab in Leukemia,A Phase 4 Study of Ocrelizumab for the Treatment of Leukemia,Interventional,Phase 4,975,2024-09-23,2025-05-26,Terminated,NIH,Crossover Assignment,Treatment,Ocrelizumab,Anti-CD20,Leukemia
NCT15614833,Study of Ocrelizumab in Leukemia,A Phase 4 Study of Ocrelizumab for the Treatment of Leukemia,Observational,Phase 4,888,2023-01-01,2023-04-08,Recruiting,Industry,Crossover Assignment,Diagnostic,Ocrelizumab,Anti-CD20,Leukemia
NCT74925460,Study of Ocrelizumab in Multiple Sclerosis,A Phase 1 Study of Ocrelizumab for the Treatment of Multiple Sclerosis,Observational,Phase 1,584,2020-04-08,2022-03-15,Completed,NIH,Crossover Assignment,Supportive Care,Ocrelizumab,Anti-CD20,Multiple Sclerosis
NCT89346782,Study of Ocrelizumab in Multiple Sclerosis,A Phase 1 Study of Ocrelizumab for the Treatment of Multiple Sclerosis,Interventional,Phase 1,368,2022-04-23,2023-05-12,Suspended,Other,Crossover Assignment,Supportive Care,Ocrelizumab,Anti-CD20,Multiple Sclerosis
NCT56705534,Study of Ocrelizumab in Multiple Sclerosis,A Phase 2 Study of Ocrelizumab for the Treatment of Multiple Sclerosis,Interventional,Phase 2,400,2021-04-08,2022-11-20,Completed,Other,Parallel Assignment,Prevention,Ocrelizumab,Anti-CD20,Multiple Sclerosis
NCT68759844,Study of Ocrelizumab in Multiple Sclerosis,A Phase 2 Study of Ocrelizumab for the Treatment of Multiple Sclerosis,Interventional,Phase 2,757,2025-03-01,2025-11-19,Suspended,Other,Crossover Assignment,Supportive Care,Ocrelizumab,Anti-CD20,Multiple Sclerosis
NCT79393535,Study of Ocrelizumab in Multiple Sclerosis,A Phase 3 Study of Ocrelizumab for the Treatment of Multiple Sclerosis,Interventional,Phase 3,900,2020-03-14,2020-07-03,Terminated,Industry,Parallel Assignment,Prevention,Ocrelizumab,Anti-CD20,Multiple Sclerosis
NCT24029614,Study of Ocrelizumab in Multiple Sclerosis,A Phase 3 Study of Ocrelizumab for the Treatment of Multiple Sclerosis,Interventional,Phase 3,566,2020-05-10,2022-03-19,Suspended,NIH,Single Group Assignment,Diagnostic,Ocrelizumab,Anti-CD20,Multiple Sclerosis
NCT30495566,Study of Ocrelizumab in Multiple Sclerosis,A Phase 3 Study of Ocrelizumab for the Treatment of Multiple Sclerosis,Observational,Phase 3,544,2021-08-31,2023-07-26,Terminated,Industry,Crossover Assignment,Treatment,Ocrelizumab,Anti-CD20,Multiple Sclerosis
NCT82052914,Study of Ocrelizumab in Multiple Sclerosis,A Phase 4 Study of Ocrelizumab for the Treatment of Multiple Sclerosis,Observational,Phase 4,949,2022-08-29,2023-05-31,Terminated,Industry,Single Group Assignment,Supportive Care,Ocrelizumab,Anti-CD20,Multiple Sclerosis
NCT86855955,Study of Ocrelizumab in Multiple Sclerosis,A Phase 4 Study of Ocrelizumab for the Treatment of Multiple Sclerosis,Observational,Phase 4,669,2023-08-10,2024-08-14,Suspended,Other,Crossover Assignment,Diagnostic,Ocrelizumab,Anti-CD20,Multiple Sclerosis
NCT92491261,Study of Trastuzumab in Breast Cancer,A Phase 1 Study of Trastuzumab for the Treatment of Breast Cancer,Interventional,Phase 1,183,2020-07-10,2020-11-30,Completed,Industry,Parallel Assignment,Diagnostic,Trastuzumab,Anti-HER2,Breast Cancer
NCT18101054,Study of Trastuzumab in Breast Cancer,A Phase 1 Study of Trastuzumab for the Treatment of Breast Cancer,Observational,Phase 1,835,2023-10-31,2024-09-11,Recruiting,Other,Parallel Assignment,Treatment,Trastuzumab,Anti-HER2,Breast Cancer
NCT38706919,Study of Trastuzumab in Breast Cancer,A Phase 1 Study of Trastuzumab for the Treatment of Breast Cancer,Observational,Phase 1,734,2023-07-18,2024-01-06,Terminated,Industry,Single Group Assignment,Prevention,Trastuzumab,Anti-HER2,Breast Cancer
NCT24725663,Study of Trastuzumab in Breast Cancer,A Phase 2 Study of Trastuzumab for the Treatment of Breast Cancer,Observational,Phase 2,77,2023-11-02,2025-02-23,Recruiting,NIH,Single Group Assignment,Prevention,Trastuzumab,Anti-HER2,Breast Cancer
NCT50442191,Study of Trastuzumab in Breast Cancer,A Phase 3 Study of Trastuzumab for the Treatment of Breast Cancer,Interventional,Phase 3,714,2022-12-06,2023-01-27,Terminated,Other,Crossover Assignment,Supportive Care,Trastuzumab,Anti-HER2,Breast Cancer
NCT53460629,Study of Trastuzumab in Breast Cancer,A Phase 4 Study of Trastuzumab for the Treatment of Breast Cancer,Observational,Phase 4,982,2021-05-30,2021-07-13,Suspended,Industry,Single Group Assignment,Prevention,Trastuzumab,Anti-HER2,Breast Cancer
NCT94079951,Study of Trastuzumab in Gastric Cancer,A Phase 1 Study of Trastuzumab for the Treatment of Gastric Cancer,Interventional,Phase 1,421,2024-12-30,2026-02-13,Completed,NIH,Crossover Assignment,Prevention,Trastuzumab,Anti-HER2,Gastric Cancer
NCT39777525,Study of Trastuzumab in Gastric Cancer,A Phase 2 Study of Trastuzumab for the Treatment of Gastric Cancer,Observational,Phase 2,42,2020-09-15,2021-08-12,Terminated,Other,Single Group Assignment,Diagnostic,Trastuzumab,Anti-HER2,Gastric Cancer
NCT33301017,Study of Trastuzumab in Gastric Cancer,A Phase 2 Study of Trastuzumab for the Treatment of Gastric Cancer,Interventional,Phase 2,840,2021-06-16,2021-12-06,Completed,NIH,Single Group Assignment,Treatment,Trastuzumab,Anti-HER2,Gastric Cancer
NCT76979198,Study of Trastuzumab in Gastric Cancer,A Phase 2 Study of Trastuzumab for the Treatment of Gastric Cancer,Interventional,Phase 2,747,2025-01-06,2025-07-18,Suspended,Other,Crossover Assignment,Supportive Care,Trastuzumab,Anti-HER2,Gastric Cancer
NCT45563241,Study of Trastuzumab in Gastric Cancer,A Phase 3 Study of Trastuzumab for the Treatment of Gastric Cancer,Interventional,Phase 3,491,2020-11-09,2022-10-29,Suspended,NIH,Single Group Assignment,Treatment,Trastuzumab,Anti-HER2,Gastric Cancer
NCT94231093,Study of Trastuzumab in Gastric Cancer,A Phase 3 Study of Trastuzumab for the Treatment of Gastric Cancer,Interventional,Phase 3,42,2021-01-30,2022-07-13,Recruiting,Industry,Parallel Assignment,Prevention,Trastuzumab,Anti-HER2,Gastric Cancer
NCT68557517,Study of Trastuzumab in Gastric Cancer,A Phase 3 Study of Trastuzumab for the Treatment of Gastric Cancer,Observational,Phase 3,264,2022-03-14,2023-09-02,Terminated,Other,Crossover Assignment,Supportive Care,Trastuzumab,Anti-HER2,Gastric Cancer
NCT69340701,Study of Trastuzumab in Gastric Cancer,A Phase 4 Study of Trastuzumab for the Treatment of Gastric Cancer,Observational,Phase 4,760,2021-12-31,2022-02-26,Completed,NIH,Parallel Assignment,Diagnostic,Trastuzumab,Anti-HER2,Gastric Cancer
NCT36116932,Study of Trastuzumab in Esophageal Cancer,A Phase 1 Study of Trastuzumab for the Treatment of Esophageal Cancer,Interventional,Phase 1,522,2024-01-22,2024-10-09,Terminated,NIH,Crossover Assignment,Prevention,Trastuzumab,Anti-HER2,Esophageal Cancer
NCT78005094,Study of Trastuzumab in Esophageal Cancer,A Phase 1 Study of Trastuzumab for the Treatment of Esophageal Cancer,Interventional,Phase 1,806,2022-11-18,2024-10-13,Suspended,NIH,Crossover Assignment,Prevention,Trastuzumab,Anti-HER2,Esophageal Cancer
NCT79923711,Study of Trastuzumab in Esophageal Cancer,A Phase 1 Study of Trastuzumab for the Treatment of Esophageal Cancer,Interventional,Phase 1,323,2023-12-16,2024-11-21,Completed,NIH,Single Group Assignment,Treatment,Trastuzumab,Anti-HER2,Esophageal Cancer
NCT29469432,Study of Trastuzumab in Esophageal Cancer,A Phase 2 Study of Trastuzumab for the Treatment of Esophageal Cancer,Observational,Phase 2,676,2023-08-04,2023-11-11,Suspended,Industry,Single Group Assignment,Treatment,Trastuzumab,Anti-HER2,Esophageal Cancer
NCT46616575,Study of Trastuzumab in Esophageal Cancer,A Phase 2 Study of Trastuzumab for the Treatment of Esophageal Cancer,Interventional,Phase 2,499,2020-10-24,2022-08-24,Recruiting,Industry,Crossover Assignment,Prevention,Trastuzumab,Anti-HER2,Esophageal Cancer
NCT84496688,Study of Trastuzumab in Esophageal Cancer,A Phase 3 Study of Trastuzumab for the Treatment of Esophageal Cancer,Interventional,Phase 3,281,2022-07-29,2023-07-11,Terminated,Industry,Single Group Assignment,Diagnostic,Trastuzumab,Anti-HER2,Esophageal Cancer
NCT12976838,Study of Trastuzumab in Esophageal Cancer,A Phase 4 Study of Trastuzumab for the Treatment of Esophageal Cancer,Observational,Phase 4,752,2022-05-14,2022-12-20,Terminated,NIH,Single Group Assignment,Diagnostic,Trastuzumab,Anti-HER2,Esophageal Cancer
NCT71697507,Study of Trastuzumab in Esophageal Cancer,A Phase 4 Study of Trastuzumab for the Treatment of Esophageal Cancer,Interventional,Phase 4,160,2023-03-30,2024-05-18,Terminated,NIH,Single Group Assignment,Diagnostic,Trastuzumab,Anti-HER2,Esophageal Cancer
NCT31880841,Study of Trastuzumab in Esophageal Cancer,A Phase 4 Study of Trastuzumab for the Treatment of Esophageal Cancer,Observational,Phase 4,270,2024-12-11,2025-10-03,Suspended,Industry,Single Group Assignment,Prevention,Trastuzumab,Anti-HER2,Esophageal Cancer
NCT43793287,Study of Pertuzumab in Breast Cancer,A Phase 1 Study of Pertuzumab for the Treatment of Breast Cancer,Observational,Phase 1,579,2020-12-30,2022-08-08,Terminated,NIH,Parallel Assignment,Supportive Care,Pertuzumab,Anti-HER2,Breast Cancer
NCT24407969,Study of Pertuzumab in Breast Cancer,A Phase 2 Study of Pertuzumab for the Treatment of Breast Cancer,Observational,Phase 2,105,2024-09-06,2026-08-09,Terminated,Other,Single Group Assignment,Diagnostic,Pertuzumab,Anti-HER2,Breast Cancer
NCT77108827,Study of Pertuzumab in Breast Cancer,A Phase 3 Study of Pertuzumab for the Treatment of Breast Cancer,Observational,Phase 3,610,2021-09-08,2022-08-26,Suspended,NIH,Crossover Assignment,Prevention,Pertuzumab,Anti-HER2,Breast Cancer
NCT58387230,Study of Pertuzumab in Breast Cancer,A Phase 3 Study of Pertuzumab for the Treatment of Breast Cancer,Observational,Phase 3,976,2022-02-19,2023-09-27,Terminated,Other,Single Group Assignment,Supportive Care,Pertuzumab,Anti-HER2,Breast Cancer
NCT30700714,Study of Pertuzumab in Breast Cancer,A Phase 3 Study of Pertuzumab for the Treatment of Breast Cancer,Interventional,Phase 3,944,2024-12-01,2026-08-06,Recruiting,Industry,Single Group Assignment,Treatment,Pertuzumab,Anti-HER2,Breast Cancer
NCT80130999,Study of Pertuzumab in Breast Cancer,A Phase 4 Study of Pertuzumab for the Treatment of Breast Cancer,Observational,Phase 4,86,2023-09-08,2024-09-08,Terminated,NIH,Single Group Assignment,Supportive Care,Pertuzumab,Anti-HER2,Breast Cancer
NCT23534320,Study of Pertuzumab in Gastric Cancer,A Phase 1 Study of Pertuzumab for the Treatment of Gastric Cancer,Observational,Phase 1,722,2022-12-07,2023-07-18,Suspended,Industry,Single Group Assignment,Treatment,Pertuzumab,Anti-HER2,Gastric Cancer
NCT90006506,Study of Pertuzumab in Gastric Cancer,A Phase 2 Study of Pertuzumab for the Treatment of Gastric Cancer,Observational,Phase 2,937,2024-12-23,2025-04-12,Suspended,NIH,Crossover Assignment,Prevention,Pertuzumab,Anti-HER2,Gastric Cancer
NCT97858564,Study of Pertuzumab in Gastric Cancer,A Phase 2 Study of Pertuzumab for the Treatment of Gastric Cancer,Interventional,Phase 2,369,2023-08-09,2024-09-23,Completed,Industry,Parallel Assignment,Supportive Care,Pertuzumab,Anti-HER2,Gastric Cancer
NCT16058594,Study of Pertuzumab in Gastric Cancer,A Phase 2 Study of Pertuzumab for the Treatment of Gastric Cancer,Observational,Phase 2,294,2020-03-23,2021-01-01,Completed,Other,Parallel Assignment,Treatment,Pertuzumab,Anti-HER2,Gastric Cancer
NCT55337370,Study of Pertuzumab in Gastric Cancer,A Phase 3 Study of Pertuzumab for the Treatment of Gastric Cancer,Interventional,Phase 3,867,2020-08-20,2020-11-22,Terminated,NIH,Single Group Assignment,Diagnostic,Pertuzumab,Anti-HER2,Gastric Cancer
NCT97183937,Study of Pertuzumab in Gastric Cancer,A Phase 3 Study of Pertuzumab for the Treatment of Gastric Cancer,Observational,Phase 3,714,2020-07-30,2021-06-04,Terminated,Other,Single Group Assignment,Treatment,Pertuzumab,Anti-HER2,Gastric Cancer
NCT24473171,Study of Pertuzumab in Gastric Cancer,A Phase 4 Study of Pertuzumab for the Treatment of Gastric Cancer,Observational,Phase 4,268,2020-08-04,2021-11-24,Recruiting,Industry,Parallel Assignment,Diagnostic,Pertuzumab,Anti-HER2,Gastric Cancer
NCT37128190,Study of Pertuzumab in Esophageal Cancer,A Phase 1 Study of Pertuzumab for the Treatment of Esophageal Cancer,Interventional,Phase 1,104,2020-07-27,2020-11-10,Suspended,Other,Single Group Assignment,Prevention,Pertuzumab,Anti-HER2,Esophageal Cancer
NCT29347995,Study of Pertuzumab in Esophageal Cancer,A Phase 1 Study of Pertuzumab for the Treatment of Esophageal Cancer,Interventional,Phase 1,261,2022-12-09,2023-12-04,Terminated,NIH,Crossover Assignment,Treatment,Pertuzumab,Anti-HER2,Esophageal Cancer
NCT28830407,Study of Pertuzumab in Esophageal Cancer,A Phase 1 Study of Pertuzumab for the Treatment of Esophageal Cancer,Observational,Phase 1,923,2024-01-25,2024-12-11,Completed,NIH,Parallel Assignment,Prevention,Pertuzumab,Anti-HER2,Esophageal Cancer
NCT60563372,Study of Pertuzumab in Esophageal Cancer,A Phase 2 Study of Pertuzumab for the Treatment of Esophageal Cancer,Interventional,Phase 2,931,2021-10-17,2023-01-10,Terminated,Other,Single Group Assignment,Diagnostic,Pertuzumab,Anti-HER2,Esophageal Cancer
NCT43322529,Study of Pertuzumab in Esophageal Cancer,A Phase 3 Study of Pertuzumab for the Treatment of Esophageal Cancer,Interventional,Phase 3,53,2023-11-19,2024-01-25,Completed,Other,Crossover Assignment,Supportive Care,Pertuzumab,Anti-HER2,Esophageal Cancer
NCT79211980,Study of Pertuzumab in Esophageal Cancer,A Phase 4 Study of Pertuzumab for the Treatment of Esophageal Cancer,Interventional,Phase 4,81,2021-08-04,2023-06-10,Recruiting,Other,Parallel Assignment,Prevention,Pertuzumab,Anti-HER2,Esophageal Cancer
NCT58590759,Study of Ado-trastuzumab emtansine in Breast Cancer,A Phase 1 Study of Ado-trastuzumab emtansine for the Treatment of Breast Cancer,Interventional,Phase 1,85,2025-03-25,2026-04-02,Terminated,NIH,Parallel Assignment,Diagnostic,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer
NCT85983103,Study of Ado-trastuzumab emtansine in Breast Cancer,A Phase 1 Study of Ado-trastuzumab emtansine for the Treatment of Breast Cancer,Observational,Phase 1,707,2020-09-28,2022-05-02,Recruiting,Other,Single Group Assignment,Supportive Care,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer
NCT11430383,Study of Ado-trastuzumab emtansine in Breast Cancer,A Phase 2 Study of Ado-trastuzumab emtansine for the Treatment of Breast Cancer,Observational,Phase 2,921,2022-08-14,2024-05-08,Recruiting,NIH,Parallel Assignment,Diagnostic,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer
NCT18866819,Study of Ado-trastuzumab emtansine in Breast Cancer,A Phase 2 Study of Ado-trastuzumab emtansine for the Treatment of Breast Cancer,Observational,Phase 2,488,2022-07-26,2023-11-22,Completed,Other,Single Group Assignment,Supportive Care,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer
NCT52824323,Study of Ado-trastuzumab emtansine in Breast Cancer,A Phase 3 Study of Ado-trastuzumab emtansine for the Treatment of Breast Cancer,Observational,Phase 3,134,2025-03-07,2025-12-31,Completed,Other,Single Group Assignment,Treatment,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer
NCT43413000,Study of Ado-trastuzumab emtansine in Breast Cancer,A Phase 3 Study of Ado-trastuzumab emtansine for the Treatment of Breast Cancer,Interventional,Phase 3,133,2024-03-27,2026-02-24,Suspended,NIH,Parallel Assignment,Treatment,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer
NCT12062929,Study of Ado-trastuzumab emtansine in Breast Cancer,A Phase 4 Study of Ado-trastuzumab emtansine for the Treatment of Breast Cancer,Observational,Phase 4,956,2024-02-26,2026-02-19,Terminated,Other,Parallel Assignment,Supportive Care,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer
NCT88116734,Study of Ado-trastuzumab emtansine in Breast Cancer,A Phase 4 Study of Ado-trastuzumab emtansine for the Treatment of Breast Cancer,Interventional,Phase 4,120,2024-02-01,2024-10-13,Suspended,NIH,Crossover Assignment,Diagnostic,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer
NCT73872146,Study of Ado-trastuzumab emtansine in Breast Cancer,A Phase 4 Study of Ado-trastuzumab emtansine for the Treatment of Breast Cancer,Observational,Phase 4,757,2023-07-01,2023-11-13,Suspended,Other,Crossover Assignment,Prevention,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer
NCT44433687,Study of Ado-trastuzumab emtansine in Gastric Cancer,A Phase 1 Study of Ado-trastuzumab emtansine for the Treatment of Gastric Cancer,Observational,Phase 1,358,2023-09-19,2024-01-15,Completed,Industry,Single Group Assignment,Prevention,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer
NCT66133386,Study of Ado-trastuzumab emtansine in Gastric Cancer,A Phase 1 Study of Ado-trastuzumab emtansine for the Treatment of Gastric Cancer,Interventional,Phase 1,371,2020-11-26,2022-03-15,Suspended,Other,Crossover Assignment,Treatment,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer
NCT25951363,Study of Ado-trastuzumab emtansine in Gastric Cancer,A Phase 2 Study of Ado-trastuzumab emtansine for the Treatment of Gastric Cancer,Interventional,Phase 2,229,2023-09-04,2024-12-22,Terminated,Industry,Single Group Assignment,Diagnostic,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer
NCT52669879,Study of Ado-trastuzumab emtansine in Gastric Cancer,A Phase 2 Study of Ado-trastuzumab emtansine for the Treatment of Gastric Cancer,Observational,Phase 2,189,2024-08-28,2025-05-27,Recruiting,Other,Parallel Assignment,Diagnostic,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer
NCT87151190,Study of Ado-trastuzumab emtansine in Gastric Cancer,A Phase 2 Study of Ado-trastuzumab emtansine for the Treatment of Gastric Cancer,Observational,Phase 2,569,2021-11-04,2023-08-26,Completed,NIH,Parallel Assignment,Prevention,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer
NCT96037081,Study of Ado-trastuzumab emtansine in Gastric Cancer,A Phase 3 Study of Ado-trastuzumab emtansine for the Treatment of Gastric Cancer,Interventional,Phase 3,880,2024-10-31,2025-09-18,Suspended,NIH,Single Group Assignment,Treatment,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer
NCT66539686,Study of Ado-trastuzumab emtansine in Gastric Cancer,A Phase 3 Study of Ado-trastuzumab emtansine for the Treatment of Gastric Cancer,Observational,Phase 3,47,2023-05-30,2023-09-01,Recruiting,NIH,Parallel Assignment,Treatment,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer
NCT16257188,Study of Ado-trastuzumab emtansine in Gastric Cancer,A Phase 3 Study of Ado-trastuzumab emtansine for the Treatment of Gastric Cancer,Observational,Phase 3,594,2023-01-13,2023-10-29,Recruiting,Other,Single Group Assignment,Prevention,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer
NCT11260808,Study of Ado-trastuzumab emtansine in Gastric Cancer,A Phase 4 Study of Ado-trastuzumab emtansine for the Treatment of Gastric Cancer,Interventional,Phase 4,905,2022-11-30,2024-08-27,Suspended,Industry,Parallel Assignment,Diagnostic,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer
NCT58072648,Study of Ado-trastuzumab emtansine in Gastric Cancer,A Phase 4 Study of Ado-trastuzumab emtansine for the Treatment of Gastric Cancer,Observational,Phase 4,279,2023-10-05,2023-12-06,Terminated,Other,Crossover Assignment,Treatment,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer
NCT66352181,Study of Ado-trastuzumab emtansine in Esophageal Cancer,A Phase 1 Study of Ado-trastuzumab emtansine for the Treatment of Esophageal Cancer,Observational,Phase 1,251,2024-02-09,2024-04-26,Suspended,Industry,Single Group Assignment,Treatment,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer
NCT66991801,Study of Ado-trastuzumab emtansine in Esophageal Cancer,A Phase 1 Study of Ado-trastuzumab emtansine for the Treatment of Esophageal Cancer,Observational,Phase 1,84,2022-03-31,2023-01-22,Terminated,Industry,Parallel Assignment,Supportive Care,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer
NCT38764835,Study of Ado-trastuzumab emtansine in Esophageal Cancer,A Phase 1 Study of Ado-trastuzumab emtansine for the Treatment of Esophageal Cancer,Interventional,Phase 1,714,2021-01-30,2022-03-07,Terminated,Industry,Crossover Assignment,Supportive Care,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer
NCT33237170,Study of Ado-trastuzumab emtansine in Esophageal Cancer,A Phase 2 Study of Ado-trastuzumab emtansine for the Treatment of Esophageal Cancer,Interventional,Phase 2,997,2022-05-19,2023-04-15,Suspended,NIH,Parallel Assignment,Prevention,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer
NCT49181561,Study of Ado-trastuzumab emtansine in Esophageal Cancer,A Phase 2 Study of Ado-trastuzumab emtansine for the Treatment of Esophageal Cancer,Interventional,Phase 2,339,2020-12-19,2022-03-28,Terminated,NIH,Single Group Assignment,Prevention,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer
NCT77286202,Study of Ado-trastuzumab emtansine in Esophageal Cancer,A Phase 3 Study of Ado-trastuzumab emtansine for the Treatment of Esophageal Cancer,Interventional,Phase 3,291,2022-10-09,2024-02-22,Recruiting,Other,Crossover Assignment,Prevention,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer
NCT21048793,Study of Ado-trastuzumab emtansine in Esophageal Cancer,A Phase 3 Study of Ado-trastuzumab emtansine for the Treatment of Esophageal Cancer,Interventional,Phase 3,689,2024-04-27,2025-05-31,Completed,Other,Crossover Assignment,Supportive Care,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer
NCT36169219,Study of Ado-trastuzumab emtansine in Esophageal Cancer,A Phase 3 Study of Ado-trastuzumab emtansine for the Treatment of Esophageal Cancer,Observational,Phase 3,82,2021-11-21,2022-03-29,Recruiting,NIH,Single Group Assignment,Treatment,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer
NCT17708466,Study of Ado-trastuzumab emtansine in Esophageal Cancer,A Phase 4 Study of Ado-trastuzumab emtansine for the Treatment of Esophageal Cancer,Interventional,Phase 4,149,2024-10-07,2026-04-22,Recruiting,Other,Single Group Assignment,Prevention,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer
NCT37664544,Study of Ado-trastuzumab emtansine in Esophageal Cancer,A Phase 4 Study of Ado-trastuzumab emtansine for the Treatment of Esophageal Cancer,Interventional,Phase 4,267,2024-10-02,2024-11-05,Recruiting,NIH,Parallel Assignment,Prevention,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer
NCT29066790,Study of Bevacizumab in Colorectal Cancer,A Phase 1 Study of Bevacizumab for the Treatment of Colorectal Cancer,Observational,Phase 1,639,2023-06-27,2025-02-03,Suspended,Other,Parallel Assignment,Prevention,Bevacizumab,Anti-VEGF,Colorectal Cancer
NCT83403465,Study of Bevacizumab in Colorectal Cancer,A Phase 2 Study of Bevacizumab for the Treatment of Colorectal Cancer,Interventional,Phase 2,84,2020-07-15,2021-05-17,Suspended,NIH,Single Group Assignment,Treatment,Bevacizumab,Anti-VEGF,Colorectal Cancer
NCT64315172,Study of Bevacizumab in Colorectal Cancer,A Phase 2 Study of Bevacizumab for the Treatment of Colorectal Cancer,Observational,Phase 2,142,2024-03-30,2025-05-10,Suspended,NIH,Parallel Assignment,Diagnostic,Bevacizumab,Anti-VEGF,Colorectal Cancer
NCT99506370,Study of Bevacizumab in Colorectal Cancer,A Phase 2 Study of Bevacizumab for the Treatment of Colorectal Cancer,Observational,Phase 2,274,2022-10-10,2024-07-30,Suspended,NIH,Parallel Assignment,Supportive Care,Bevacizumab,Anti-VEGF,Colorectal Cancer
NCT82032992,Study of Bevacizumab in Colorectal Cancer,A Phase 3 Study of Bevacizumab for the Treatment of Colorectal Cancer,Interventional,Phase 3,945,2021-03-27,2023-01-15,Completed,Industry,Crossover Assignment,Supportive Care,Bevacizumab,Anti-VEGF,Colorectal Cancer
NCT62713148,Study of Bevacizumab in Colorectal Cancer,A Phase 3 Study of Bevacizumab for the Treatment of Colorectal Cancer,Interventional,Phase 3,744,2021-09-22,2022-10-17,Terminated,Other,Crossover Assignment,Treatment,Bevacizumab,Anti-VEGF,Colorectal Cancer
NCT46207933,Study of Bevacizumab in Colorectal Cancer,A Phase 4 Study of Bevacizumab for the Treatment of Colorectal Cancer,Interventional,Phase 4,542,2023-02-28,2024-03-20,Suspended,Other,Crossover Assignment,Treatment,Bevacizumab,Anti-VEGF,Colorectal Cancer
NCT78174268,Study of Bevacizumab in Colorectal Cancer,A Phase 4 Study of Bevacizumab for the Treatment of Colorectal Cancer,Observational,Phase 4,187,2025-04-30,2026-06-23,Terminated,Industry,Crossover Assignment,Prevention,Bevacizumab,Anti-VEGF,Colorectal Cancer
NCT77476911,Study of Bevacizumab in Colorectal Cancer,A Phase 4 Study of Bevacizumab for the Treatment of Colorectal Cancer,Observational,Phase 4,36,2022-03-14,2022-08-10,Terminated,NIH,Parallel Assignment,Diagnostic,Bevacizumab,Anti-VEGF,Colorectal Cancer
NCT71882375,Study of Bevacizumab in Lung Cancer,A Phase 1 Study of Bevacizumab for the Treatment of Lung Cancer,Observational,Phase 1,883,2022-02-28,2023-03-04,Suspended,Industry,Crossover Assignment,Supportive Care,Bevacizumab,Anti-VEGF,Lung Cancer
NCT67291452,Study of Bevacizumab in Lung Cancer,A Phase 1 Study of Bevacizumab for the Treatment of Lung Cancer,Observational,Phase 1,155,2024-12-04,2025-08-01,Recruiting,Other,Crossover Assignment,Prevention,Bevacizumab,Anti-VEGF,Lung Cancer
NCT10154072,Study of Bevacizumab in Lung Cancer,A Phase 2 Study of Bevacizumab for the Treatment of Lung Cancer,Interventional,Phase 2,452,2022-07-26,2024-05-12,Recruiting,NIH,Parallel Assignment,Treatment,Bevacizumab,Anti-VEGF,Lung Cancer
NCT12243516,Study of Bevacizumab in Lung Cancer,A Phase 2 Study of Bevacizumab for the Treatment of Lung Cancer,Observational,Phase 2,821,2023-01-24,2023-02-27,Completed,NIH,Single Group Assignment,Diagnostic,Bevacizumab,Anti-VEGF,Lung Cancer
NCT52650141,Study of Bevacizumab in Lung Cancer,A Phase 2 Study of Bevacizumab for the Treatment of Lung Cancer,Interventional,Phase 2,827,2020-03-26,2020-11-27,Recruiting,Other,Parallel Assignment,Supportive Care,Bevacizumab,Anti-VEGF,Lung Cancer
NCT11919204,Study of Bevacizumab in Lung Cancer,A Phase 3 Study of Bevacizumab for the Treatment of Lung Cancer,Observational,Phase 3,375,2022-12-30,2023-02-26,Completed,NIH,Single Group Assignment,Treatment,Bevacizumab,Anti-VEGF,Lung Cancer
NCT61859305,Study of Bevacizumab in Lung Cancer,A Phase 4 Study of Bevacizumab for the Treatment of Lung Cancer,Observational,Phase 4,298,2022-12-07,2023-07-24,Recruiting,NIH,Parallel Assignment,Treatment,Bevacizumab,Anti-VEGF,Lung Cancer
NCT62533883,Study of Bevacizumab in Lung Cancer,A Phase 4 Study of Bevacizumab for the Treatment of Lung Cancer,Observational,Phase 4,329,2021-02-24,2022-03-21,Suspended,Industry,Parallel Assignment,Diagnostic,Bevacizumab,Anti-VEGF,Lung Cancer
NCT10274697,Study of Bevacizumab in Ovarian Cancer,A Phase 1 Study of Bevacizumab for the Treatment of Ovarian Cancer,Interventional,Phase 1,463,2025-05-02,2026-08-05,Recruiting,NIH,Parallel Assignment,Prevention,Bevacizumab,Anti-VEGF,Ovarian Cancer
NCT76174895,Study of Bevacizumab in Ovarian Cancer,A Phase 1 Study of Bevacizumab for the Treatment of Ovarian Cancer,Observational,Phase 1,418,2023-01-11,2024-03-19,Suspended,Industry,Crossover Assignment,Supportive Care,Bevacizumab,Anti-VEGF,Ovarian Cancer
NCT17855717,Study of Bevacizumab in Ovarian Cancer,A Phase 2 Study of Bevacizumab for the Treatment of Ovarian Cancer,Observational,Phase 2,901,2021-05-29,2022-09-29,Suspended,Other,Crossover Assignment,Supportive Care,Bevacizumab,Anti-VEGF,Ovarian Cancer
NCT44443320,Study of Bevacizumab in Ovarian Cancer,A Phase 2 Study of Bevacizumab for the Treatment of Ovarian Cancer,Observational,Phase 2,537,2023-07-25,2025-06-30,Suspended,NIH,Crossover Assignment,Treatment,Bevacizumab,Anti-VEGF,Ovarian Cancer
NCT57372270,Study of Bevacizumab in Ovarian Cancer,A Phase 2 Study of Bevacizumab for the Treatment of Ovarian Cancer,Interventional,Phase 2,320,2025-04-18,2027-04-14,Terminated,NIH,Crossover Assignment,Supportive Care,Bevacizumab,Anti-VEGF,Ovarian Cancer
NCT22593637,Study of Bevacizumab in Ovarian Cancer,A Phase 3 Study of Bevacizumab for the Treatment of Ovarian Cancer,Observational,Phase 3,678,2020-05-02,2020-08-11,Suspended,Other,Parallel Assignment,Supportive Care,Bevacizumab,Anti-VEGF,Ovarian Cancer
NCT40222790,Study of Bevacizumab in Ovarian Cancer,A Phase 3 Study of Bevacizumab for the Treatment of Ovarian Cancer,Observational,Phase 3,215,2022-09-22,2024-05-03,Completed,Industry,Crossover Assignment,Diagnostic,Bevacizumab,Anti-VEGF,Ovarian Cancer
NCT29125103,Study of Bevacizumab in Ovarian Cancer,A Phase 4 Study of Bevacizumab for the Treatment of Ovarian Cancer,Interventional,Phase 4,876,2024-07-06,2025-09-23,Recruiting,NIH,Parallel Assignment,Prevention,Bevacizumab,Anti-VEGF,Ovarian Cancer
NCT15911018,Study of Ranibizumab in Colorectal Cancer,A Phase 1 Study of Ranibizumab for the Treatment of Colorectal Cancer,Interventional,Phase 1,472,2022-03-09,2024-03-05,Terminated,Other,Crossover Assignment,Diagnostic,Ranibizumab,Anti-VEGF,Colorectal Cancer
NCT79899332,Study of Ranibizumab in Colorectal Cancer,A Phase 1 Study of Ranibizumab for the Treatment of Colorectal Cancer,Observational,Phase 1,645,2025-03-19,2025-05-27,Suspended,Industry,Parallel Assignment,Diagnostic,Ranibizumab,Anti-VEGF,Colorectal Cancer
NCT56800937,Study of Ranibizumab in Colorectal Cancer,A Phase 2 Study of Ranibizumab for the Treatment of Colorectal Cancer,Interventional,Phase 2,726,2020-08-15,2020-12-07,Suspended,NIH,Single Group Assignment,Prevention,Ranibizumab,Anti-VEGF,Colorectal Cancer
NCT42097829,Study of Ranibizumab in Colorectal Cancer,A Phase 2 Study of Ranibizumab for the Treatment of Colorectal Cancer,Interventional,Phase 2,90,2023-12-21,2025-11-06,Completed,Industry,Crossover Assignment,Diagnostic,Ranibizumab,Anti-VEGF,Colorectal Cancer
NCT59772960,Study of Ranibizumab in Colorectal Cancer,A Phase 2 Study of Ranibizumab for the Treatment of Colorectal Cancer,Observational,Phase 2,441,2023-03-04,2024-04-17,Recruiting,Other,Single Group Assignment,Treatment,Ranibizumab,Anti-VEGF,Colorectal Cancer
NCT43823427,Study of Ranibizumab in Colorectal Cancer,A Phase 3 Study of Ranibizumab for the Treatment of Colorectal Cancer,Interventional,Phase 3,39,2020-06-21,2021-09-05,Suspended,NIH,Crossover Assignment,Prevention,Ranibizumab,Anti-VEGF,Colorectal Cancer
NCT18471639,Study of Ranibizumab in Colorectal Cancer,A Phase 3 Study of Ranibizumab for the Treatment of Colorectal Cancer,Observational,Phase 3,582,2024-11-27,2026-04-21,Suspended,NIH,Parallel Assignment,Diagnostic,Ranibizumab,Anti-VEGF,Colorectal Cancer
NCT65835095,Study of Ranibizumab in Colorectal Cancer,A Phase 3 Study of Ranibizumab for the Treatment of Colorectal Cancer,Interventional,Phase 3,161,2022-12-04,2024-03-10,Terminated,NIH,Crossover Assignment,Treatment,Ranibizumab,Anti-VEGF,Colorectal Cancer
NCT71331350,Study of Ranibizumab in Colorectal Cancer,A Phase 4 Study of Ranibizumab for the Treatment of Colorectal Cancer,Observational,Phase 4,947,2023-08-09,2024-06-21,Suspended,NIH,Single Group Assignment,Diagnostic,Ranibizumab,Anti-VEGF,Colorectal Cancer
NCT83319508,Study of Ranibizumab in Colorectal Cancer,A Phase 4 Study of Ranibizumab for the Treatment of Colorectal Cancer,Observational,Phase 4,288,2023-06-30,2023-10-17,Completed,Other,Parallel Assignment,Supportive Care,Ranibizumab,Anti-VEGF,Colorectal Cancer
NCT80748979,Study of Ranibizumab in Lung Cancer,A Phase 1 Study of Ranibizumab for the Treatment of Lung Cancer,Interventional,Phase 1,730,2024-09-08,2025-02-01,Suspended,Other,Parallel Assignment,Supportive Care,Ranibizumab,Anti-VEGF,Lung Cancer
NCT86164621,Study of Ranibizumab in Lung Cancer,A Phase 1 Study of Ranibizumab for the Treatment of Lung Cancer,Interventional,Phase 1,859,2023-12-03,2025-06-10,Terminated,Industry,Parallel Assignment,Prevention,Ranibizumab,Anti-VEGF,Lung Cancer
NCT15283476,Study of Ranibizumab in Lung Cancer,A Phase 1 Study of Ranibizumab for the Treatment of Lung Cancer,Interventional,Phase 1,299,2022-01-09,2022-09-15,Recruiting,Industry,Parallel Assignment,Treatment,Ranibizumab,Anti-VEGF,Lung Cancer
NCT79560343,Study of Ranibizumab in Lung Cancer,A Phase 2 Study of Ranibizumab for the Treatment of Lung Cancer,Interventional,Phase 2,225,2025-01-18,2025-12-12,Suspended,NIH,Parallel Assignment,Treatment,Ranibizumab,Anti-VEGF,Lung Cancer
NCT30751078,Study of Ranibizumab in Lung Cancer,A Phase 2 Study of Ranibizumab for the Treatment of Lung Cancer,Interventional,Phase 2,173,2020-08-22,2021-06-19,Completed,Other,Single Group Assignment,Prevention,Ranibizumab,Anti-VEGF,Lung Cancer
NCT85616530,Study of Ranibizumab in Lung Cancer,A Phase 2 Study of Ranibizumab for the Treatment of Lung Cancer,Observational,Phase 2,531,2024-06-14,2025-09-14,Terminated,NIH,Parallel Assignment,Diagnostic,Ranibizumab,Anti-VEGF,Lung Cancer
NCT53998641,Study of Ranibizumab in Lung Cancer,A Phase 3 Study of Ranibizumab for the Treatment of Lung Cancer,Interventional,Phase 3,434,2021-09-25,2023-04-16,Terminated,NIH,Single Group Assignment,Prevention,Ranibizumab,Anti-VEGF,Lung Cancer
NCT71515230,Study of Ranibizumab in Lung Cancer,A Phase 3 Study of Ranibizumab for the Treatment of Lung Cancer,Observational,Phase 3,252,2024-03-08,2025-04-21,Suspended,Industry,Single Group Assignment,Supportive Care,Ranibizumab,Anti-VEGF,Lung Cancer
NCT65927640,Study of Ranibizumab in Lung Cancer,A Phase 4 Study of Ranibizumab for the Treatment of Lung Cancer,Observational,Phase 4,227,2021-07-04,2022-02-08,Completed,Industry,Single Group Assignment,Prevention,Ranibizumab,Anti-VEGF,Lung Cancer
NCT12503048,Study of Ranibizumab in Lung Cancer,A Phase 4 Study of Ranibizumab for the Treatment of Lung Cancer,Observational,Phase 4,918,2024-09-21,2026-04-20,Recruiting,Other,Crossover Assignment,Treatment,Ranibizumab,Anti-VEGF,Lung Cancer
NCT33948851,Study of Ranibizumab in Ovarian Cancer,A Phase 1 Study of Ranibizumab for the Treatment of Ovarian Cancer,Observational,Phase 1,574,2022-01-25,2022-06-11,Terminated,Industry,Crossover Assignment,Treatment,Ranibizumab,Anti-VEGF,Ovarian Cancer
NCT21950629,Study of Ranibizumab in Ovarian Cancer,A Phase 1 Study of Ranibizumab for the Treatment of Ovarian Cancer,Observational,Phase 1,701,2023-03-03,2023-06-19,Suspended,Industry,Single Group Assignment,Diagnostic,Ranibizumab,Anti-VEGF,Ovarian Cancer
NCT66231169,Study of Ranibizumab in Ovarian Cancer,A Phase 2 Study of Ranibizumab for the Treatment of Ovarian Cancer,Observational,Phase 2,612,2025-01-16,2025-11-15,Completed,NIH,Crossover Assignment,Prevention,Ranibizumab,Anti-VEGF,Ovarian Cancer
NCT92095482,Study of Ranibizumab in Ovarian Cancer,A Phase 3 Study of Ranibizumab for the Treatment of Ovarian Cancer,Observational,Phase 3,904,2024-02-29,2025-12-04,Terminated,Industry,Single Group Assignment,Supportive Care,Ranibizumab,Anti-VEGF,Ovarian Cancer
NCT46905073,Study of Ranibizumab in Ovarian Cancer,A Phase 3 Study of Ranibizumab for the Treatment of Ovarian Cancer,Observational,Phase 3,106,2020-06-27,2021-03-02,Terminated,Other,Crossover Assignment,Diagnostic,Ranibizumab,Anti-VEGF,Ovarian Cancer
NCT50887043,Study of Ranibizumab in Ovarian Cancer,A Phase 3 Study of Ranibizumab for the Treatment of Ovarian Cancer,Observational,Phase 3,368,2024-11-17,2026-08-20,Completed,Industry,Crossover Assignment,Treatment,Ranibizumab,Anti-VEGF,Ovarian Cancer
NCT32940316,Study of Ranibizumab in Ovarian Cancer,A Phase 4 Study of Ranibizumab for the Treatment of Ovarian Cancer,Interventional,Phase 4,647,2023-02-01,2024-04-20,Terminated,Other,Crossover Assignment,Treatment,Ranibizumab,Anti-VEGF,Ovarian Cancer
NCT32427062,Study of Ranibizumab in Ovarian Cancer,A Phase 4 Study of Ranibizumab for the Treatment of Ovarian Cancer,Interventional,Phase 4,839,2021-01-12,2021-11-26,Suspended,Other,Crossover Assignment,Prevention,Ranibizumab,Anti-VEGF,Ovarian Cancer
NCT30875486,Study of Ranibizumab in Ovarian Cancer,A Phase 4 Study of Ranibizumab for the Treatment of Ovarian Cancer,Observational,Phase 4,637,2025-03-06,2025-07-16,Recruiting,Other,Crossover Assignment,Diagnostic,Ranibizumab,Anti-VEGF,Ovarian Cancer
NCT89856329,Study of Aflibercept in Colorectal Cancer,A Phase 1 Study of Aflibercept for the Treatment of Colorectal Cancer,Observational,Phase 1,188,2020-06-30,2020-10-30,Completed,Other,Crossover Assignment,Supportive Care,Aflibercept,Anti-VEGF,Colorectal Cancer
NCT38428726,Study of Aflibercept in Colorectal Cancer,A Phase 1 Study of Aflibercept for the Treatment of Colorectal Cancer,Observational,Phase 1,807,2020-12-14,2021-03-14,Suspended,Industry,Crossover Assignment,Supportive Care,Aflibercept,Anti-VEGF,Colorectal Cancer
NCT69062284,Study of Aflibercept in Colorectal Cancer,A Phase 1 Study of Aflibercept for the Treatment of Colorectal Cancer,Interventional,Phase 1,307,2025-03-18,2026-03-22,Completed,NIH,Crossover Assignment,Prevention,Aflibercept,Anti-VEGF,Colorectal Cancer
NCT60969132,Study of Aflibercept in Colorectal Cancer,A Phase 2 Study of Aflibercept for the Treatment of Colorectal Cancer,Observational,Phase 2,951,2021-04-24,2021-12-02,Completed,Other,Crossover Assignment,Prevention,Aflibercept,Anti-VEGF,Colorectal Cancer
NCT93347085,Study of Aflibercept in Colorectal Cancer,A Phase 2 Study of Aflibercept for the Treatment of Colorectal Cancer,Interventional,Phase 2,227,2021-09-29,2022-01-17,Suspended,NIH,Crossover Assignment,Treatment,Aflibercept,Anti-VEGF,Colorectal Cancer
NCT42621682,Study of Aflibercept in Colorectal Cancer,A Phase 3 Study of Aflibercept for the Treatment of Colorectal Cancer,Interventional,Phase 3,554,2022-10-23,2024-09-04,Suspended,NIH,Crossover Assignment,Treatment,Aflibercept,Anti-VEGF,Colorectal Cancer
NCT46851208,Study of Aflibercept in Colorectal Cancer,A Phase 3 Study of Aflibercept for the Treatment of Colorectal Cancer,Interventional,Phase 3,940,2024-12-15,2026-07-31,Recruiting,NIH,Parallel Assignment,Prevention,Aflibercept,Anti-VEGF,Colorectal Cancer
NCT71538311,Study of Aflibercept in Colorectal Cancer,A Phase 3 Study of Aflibercept for the Treatment of Colorectal Cancer,Observational,Phase 3,526,2021-07-26,2022-06-17,Suspended,Other,Parallel Assignment,Diagnostic,Aflibercept,Anti-VEGF,Colorectal Cancer
NCT22125377,Study of Aflibercept in Colorectal Cancer,A Phase 4 Study of Aflibercept for the Treatment of Colorectal Cancer,Observational,Phase 4,389,2024-03-15,2026-03-09,Terminated,Other,Parallel Assignment,Treatment,Aflibercept,Anti-VEGF,Colorectal Cancer
NCT38335861,Study of Aflibercept in Lung Cancer,A Phase 1 Study of Aflibercept for the Treatment of Lung Cancer,Observational,Phase 1,458,2024-10-28,2025-09-26,Completed,NIH,Parallel Assignment,Diagnostic,Aflibercept,Anti-VEGF,Lung Cancer
NCT63206947,Study of Aflibercept in Lung Cancer,A Phase 1 Study of Aflibercept for the Treatment of Lung Cancer,Interventional,Phase 1,737,2020-08-25,2021-07-02,Terminated,Industry,Single Group Assignment,Supportive Care,Aflibercept,Anti-VEGF,Lung Cancer
NCT53563341,Study of Aflibercept in Lung Cancer,A Phase 2 Study of Aflibercept for the Treatment of Lung Cancer,Observational,Phase 2,319,2024-03-07,2025-08-13,Terminated,Industry,Parallel Assignment,Supportive Care,Aflibercept,Anti-VEGF,Lung Cancer
NCT94925643,Study of Aflibercept in Lung Cancer,A Phase 2 Study of Aflibercept for the Treatment of Lung Cancer,Interventional,Phase 2,472,2021-06-29,2021-12-15,Terminated,Other,Crossover Assignment,Treatment,Aflibercept,Anti-VEGF,Lung Cancer
NCT38572955,Study of Aflibercept in Lung Cancer,A Phase 2 Study of Aflibercept for the Treatment of Lung Cancer,Observational,Phase 2,391,2024-01-26,2024-10-07,Suspended,Other,Parallel Assignment,Prevention,Aflibercept,Anti-VEGF,Lung Cancer
NCT44754290,Study of Aflibercept in Lung Cancer,A Phase 3 Study of Aflibercept for the Treatment of Lung Cancer,Observational,Phase 3,490,2020-10-26,2022-02-22,Terminated,Industry,Crossover Assignment,Supportive Care,Aflibercept,Anti-VEGF,Lung Cancer
NCT65193257,Study of Aflibercept in Lung Cancer,A Phase 3 Study of Aflibercept for the Treatment of Lung Cancer,Interventional,Phase 3,890,2023-10-22,2024-12-18,Suspended,Industry,Single Group Assignment,Supportive Care,Aflibercept,Anti-VEGF,Lung Cancer
NCT58362627,Study of Aflibercept in Lung Cancer,A Phase 4 Study of Aflibercept for the Treatment of Lung Cancer,Interventional,Phase 4,443,2023-04-14,2023-11-24,Suspended,Other,Crossover Assignment,Treatment,Aflibercept,Anti-VEGF,Lung Cancer
NCT58416245,Study of Aflibercept in Lung Cancer,A Phase 4 Study of Aflibercept for the Treatment of Lung Cancer,Interventional,Phase 4,695,2021-06-30,2022-09-08,Terminated,NIH,Crossover Assignment,Diagnostic,Aflibercept,Anti-VEGF,Lung Cancer
NCT68466127,Study of Aflibercept in Lung Cancer,A Phase 4 Study of Aflibercept for the Treatment of Lung Cancer,Observational,Phase 4,574,2024-05-05,2025-06-12,Suspended,NIH,Single Group Assignment,Treatment,Aflibercept,Anti-VEGF,Lung Cancer
NCT93609410,Study of Aflibercept in Ovarian Cancer,A Phase 1 Study of Aflibercept for the Treatment of Ovarian Cancer,Observational,Phase 1,178,2021-01-05,2021-07-12,Completed,Industry,Parallel Assignment,Treatment,Aflibercept,Anti-VEGF,Ovarian Cancer
NCT64850646,Study of Aflibercept in Ovarian Cancer,A Phase 2 Study of Aflibercept for the Treatment of Ovarian Cancer,Interventional,Phase 2,873,2020-04-28,2021-11-27,Recruiting,Industry,Single Group Assignment,Diagnostic,Aflibercept,Anti-VEGF,Ovarian Cancer
NCT79583245,Study of Aflibercept in Ovarian Cancer,A Phase 3 Study of Aflibercept for the Treatment of Ovarian Cancer,Observational,Phase 3,54,2023-11-13,2024-01-28,Completed,Other,Crossover Assignment,Prevention,Aflibercept,Anti-VEGF,Ovarian Cancer
NCT85193572,Study of Aflibercept in Ovarian Cancer,A Phase 4 Study of Aflibercept for the Treatment of Ovarian Cancer,Interventional,Phase 4,592,2020-08-27,2021-05-03,Suspended,Industry,Single Group Assignment,Treatment,Aflibercept,Anti-VEGF,Ovarian Cancer
NCT61798014,Study of Aflibercept in Ovarian Cancer,A Phase 4 Study of Aflibercept for the Treatment of Ovarian Cancer,Interventional,Phase 4,764,2023-11-19,2024-06-27,Recruiting,NIH,Crossover Assignment,Supportive Care,Aflibercept,Anti-VEGF,Ovarian Cancer
NCT20608576,Study of Aflibercept in Ovarian Cancer,A Phase 4 Study of Aflibercept for the Treatment of Ovarian Cancer,Interventional,Phase 4,947,2020-09-27,2021-04-20,Suspended,Industry,Single Group Assignment,Diagnostic,Aflibercept,Anti-VEGF,Ovarian Cancer
NCT16668712,Study of Pembrolizumab in Melanoma,A Phase 1 Study of Pembrolizumab for the Treatment of Melanoma,Observational,Phase 1,563,2022-11-30,2024-01-21,Completed,NIH,Crossover Assignment,Supportive Care,Pembrolizumab,Anti-PD-1,Melanoma
NCT21782304,Study of Pembrolizumab in Melanoma,A Phase 1 Study of Pembrolizumab for the Treatment of Melanoma,Interventional,Phase 1,949,2023-08-26,2024-01-01,Recruiting,NIH,Parallel Assignment,Treatment,Pembrolizumab,Anti-PD-1,Melanoma
NCT44376605,Study of Pembrolizumab in Melanoma,A Phase 1 Study of Pembrolizumab for the Treatment of Melanoma,Observational,Phase 1,883,2021-07-29,2023-03-09,Completed,Other,Parallel Assignment,Treatment,Pembrolizumab,Anti-PD-1,Melanoma
NCT36962884,Study of Pembrolizumab in Melanoma,A Phase 2 Study of Pembrolizumab for the Treatment of Melanoma,Interventional,Phase 2,223,2022-08-06,2024-07-22,Completed,Other,Single Group Assignment,Supportive Care,Pembrolizumab,Anti-PD-1,Melanoma
NCT21130707,Study of Pembrolizumab in Melanoma,A Phase 2 Study of Pembrolizumab for the Treatment of Melanoma,Observational,Phase 2,443,2023-05-15,2023-12-01,Suspended,NIH,Parallel Assignment,Treatment,Pembrolizumab,Anti-PD-1,Melanoma
NCT63699390,Study of Pembrolizumab in Melanoma,A Phase 2 Study of Pembrolizumab for the Treatment of Melanoma,Interventional,Phase 2,171,2021-05-27,2021-11-28,Suspended,NIH,Parallel Assignment,Diagnostic,Pembrolizumab,Anti-PD-1,Melanoma
NCT29932113,Study of Pembrolizumab in Melanoma,A Phase 3 Study of Pembrolizumab for the Treatment of Melanoma,Interventional,Phase 3,236,2021-09-21,2023-04-23,Terminated,NIH,Crossover Assignment,Diagnostic,Pembrolizumab,Anti-PD-1,Melanoma
NCT29738899,Study of Pembrolizumab in Melanoma,A Phase 3 Study of Pembrolizumab for the Treatment of Melanoma,Observational,Phase 3,279,2020-05-16,2020-08-23,Suspended,Other,Crossover Assignment,Supportive Care,Pembrolizumab,Anti-PD-1,Melanoma
NCT90042183,Study of Pembrolizumab in Melanoma,A Phase 3 Study of Pembrolizumab for the Treatment of Melanoma,Observational,Phase 3,268,2021-10-23,2023-06-17,Completed,NIH,Crossover Assignment,Supportive Care,Pembrolizumab,Anti-PD-1,Melanoma
NCT15817360,Study of Pembrolizumab in Melanoma,A Phase 4 Study of Pembrolizumab for the Treatment of Melanoma,Interventional,Phase 4,396,2022-12-06,2024-05-28,Recruiting,NIH,Single Group Assignment,Diagnostic,Pembrolizumab,Anti-PD-1,Melanoma
NCT50144995,Study of Pembrolizumab in Melanoma,A Phase 4 Study of Pembrolizumab for the Treatment of Melanoma,Observational,Phase 4,406,2022-01-11,2022-03-16,Recruiting,Other,Parallel Assignment,Prevention,Pembrolizumab,Anti-PD-1,Melanoma
NCT64224792,Study of Pembrolizumab in Melanoma,A Phase 4 Study of Pembrolizumab for the Treatment of Melanoma,Interventional,Phase 4,502,2021-05-04,2021-10-06,Suspended,NIH,Parallel Assignment,Treatment,Pembrolizumab,Anti-PD-1,Melanoma
NCT31924506,Study of Pembrolizumab in Lung Cancer,A Phase 1 Study of Pembrolizumab for the Treatment of Lung Cancer,Observational,Phase 1,959,2023-04-23,2024-10-24,Suspended,Industry,Parallel Assignment,Treatment,Pembrolizumab,Anti-PD-1,Lung Cancer
NCT29868322,Study of Pembrolizumab in Lung Cancer,A Phase 2 Study of Pembrolizumab for the Treatment of Lung Cancer,Observational,Phase 2,874,2022-05-10,2024-03-06,Suspended,NIH,Crossover Assignment,Diagnostic,Pembrolizumab,Anti-PD-1,Lung Cancer
NCT34939790,Study of Pembrolizumab in Lung Cancer,A Phase 2 Study of Pembrolizumab for the Treatment of Lung Cancer,Interventional,Phase 2,765,2021-02-23,2022-04-22,Suspended,Industry,Parallel Assignment,Prevention,Pembrolizumab,Anti-PD-1,Lung Cancer
NCT81489568,Study of Pembrolizumab in Lung Cancer,A Phase 2 Study of Pembrolizumab for the Treatment of Lung Cancer,Observational,Phase 2,863,2021-04-15,2023-02-06,Completed,Industry,Crossover Assignment,Prevention,Pembrolizumab,Anti-PD-1,Lung Cancer
NCT37990206,Study of Pembrolizumab in Lung Cancer,A Phase 3 Study of Pembrolizumab for the Treatment of Lung Cancer,Observational,Phase 3,78,2021-09-23,2022-08-23,Completed,NIH,Parallel Assignment,Prevention,Pembrolizumab,Anti-PD-1,Lung Cancer
NCT10545464,Study of Pembrolizumab in Lung Cancer,A Phase 3 Study of Pembrolizumab for the Treatment of Lung Cancer,Observational,Phase 3,45,2021-04-14,2022-08-04,Suspended,Other,Single Group Assignment,Treatment,Pembrolizumab,Anti-PD-1,Lung Cancer
NCT97611651,Study of Pembrolizumab in Lung Cancer,A Phase 3 Study of Pembrolizumab for the Treatment of Lung Cancer,Observational,Phase 3,125,2023-11-28,2025-10-08,Suspended,Industry,Crossover Assignment,Prevention,Pembrolizumab,Anti-PD-1,Lung Cancer
NCT14202147,Study of Pembrolizumab in Lung Cancer,A Phase 4 Study of Pembrolizumab for the Treatment of Lung Cancer,Interventional,Phase 4,39,2021-10-30,2022-02-28,Suspended,Other,Crossover Assignment,Supportive Care,Pembrolizumab,Anti-PD-1,Lung Cancer
NCT50717175,Study of Pembrolizumab in Lymphoma,A Phase 1 Study of Pembrolizumab for the Treatment of Lymphoma,Observational,Phase 1,816,2024-10-22,2025-01-25,Terminated,NIH,Crossover Assignment,Prevention,Pembrolizumab,Anti-PD-1,Lymphoma
NCT62099161,Study of Pembrolizumab in Lymphoma,A Phase 1 Study of Pembrolizumab for the Treatment of Lymphoma,Interventional,Phase 1,647,2023-01-09,2023-04-11,Terminated,Industry,Parallel Assignment,Prevention,Pembrolizumab,Anti-PD-1,Lymphoma
NCT28982172,Study of Pembrolizumab in Lymphoma,A Phase 1 Study of Pembrolizumab for the Treatment of Lymphoma,Observational,Phase 1,876,2023-04-13,2025-03-21,Terminated,Industry,Single Group Assignment,Diagnostic,Pembrolizumab,Anti-PD-1,Lymphoma
NCT63954740,Study of Pembrolizumab in Lymphoma,A Phase 2 Study of Pembrolizumab for the Treatment of Lymphoma,Interventional,Phase 2,770,2020-10-07,2021-02-14,Completed,NIH,Crossover Assignment,Diagnostic,Pembrolizumab,Anti-PD-1,Lymphoma
NCT37315303,Study of Pembrolizumab in Lymphoma,A Phase 2 Study of Pembrolizumab for the Treatment of Lymphoma,Interventional,Phase 2,755,2021-08-31,2022-03-04,Recruiting,Industry,Crossover Assignment,Treatment,Pembrolizumab,Anti-PD-1,Lymphoma
NCT85480230,Study of Pembrolizumab in Lymphoma,A Phase 2 Study of Pembrolizumab for the Treatment of Lymphoma,Observational,Phase 2,538,2021-02-17,2021-08-08,Completed,Other,Crossover Assignment,Supportive Care,Pembrolizumab,Anti-PD-1,Lymphoma
NCT23711365,Study of Pembrolizumab in Lymphoma,A Phase 3 Study of Pembrolizumab for the Treatment of Lymphoma,Interventional,Phase 3,251,2024-08-22,2025-06-20,Terminated,NIH,Single Group Assignment,Treatment,Pembrolizumab,Anti-PD-1,Lymphoma
NCT35260372,Study of Pembrolizumab in Lymphoma,A Phase 3 Study of Pembrolizumab for the Treatment of Lymphoma,Observational,Phase 3,303,2020-08-10,2021-08-16,Recruiting,Industry,Parallel Assignment,Diagnostic,Pembrolizumab,Anti-PD-1,Lymphoma
NCT82427229,Study of Pembrolizumab in Lymphoma,A Phase 4 Study of Pembrolizumab for the Treatment of Lymphoma,Observational,Phase 4,868,2023-02-09,2024-11-02,Suspended,Industry,Parallel Assignment,Prevention,Pembrolizumab,Anti-PD-1,Lymphoma
NCT83392707,Study of Pembrolizumab in Lymphoma,A Phase 4 Study of Pembrolizumab for the Treatment of Lymphoma,Observational,Phase 4,323,2025-02-19,2026-04-10,Suspended,Other,Parallel Assignment,Treatment,Pembrolizumab,Anti-PD-1,Lymphoma
NCT35460790,Study of Pembrolizumab in Lymphoma,A Phase 4 Study of Pembrolizumab for the Treatment of Lymphoma,Observational,Phase 4,30,2020-05-25,2020-08-26,Suspended,Industry,Parallel Assignment,Treatment,Pembrolizumab,Anti-PD-1,Lymphoma
NCT75842185,Study of Nivolumab in Melanoma,A Phase 1 Study of Nivolumab for the Treatment of Melanoma,Observational,Phase 1,525,2023-04-30,2024-07-16,Suspended,NIH,Single Group Assignment,Treatment,Nivolumab,Anti-PD-1,Melanoma
NCT17518948,Study of Nivolumab in Melanoma,A Phase 1 Study of Nivolumab for the Treatment of Melanoma,Interventional,Phase 1,564,2024-10-29,2025-07-19,Terminated,NIH,Single Group Assignment,Diagnostic,Nivolumab,Anti-PD-1,Melanoma
NCT80331730,Study of Nivolumab in Melanoma,A Phase 1 Study of Nivolumab for the Treatment of Melanoma,Interventional,Phase 1,424,2023-01-24,2023-05-17,Recruiting,Other,Single Group Assignment,Treatment,Nivolumab,Anti-PD-1,Melanoma
NCT86459434,Study of Nivolumab in Melanoma,A Phase 2 Study of Nivolumab for the Treatment of Melanoma,Interventional,Phase 2,425,2025-02-04,2026-02-17,Suspended,Industry,Crossover Assignment,Prevention,Nivolumab,Anti-PD-1,Melanoma
NCT39967869,Study of Nivolumab in Melanoma,A Phase 3 Study of Nivolumab for the Treatment of Melanoma,Interventional,Phase 3,698,2023-01-09,2023-11-04,Recruiting,Industry,Single Group Assignment,Supportive Care,Nivolumab,Anti-PD-1,Melanoma
NCT24341371,Study of Nivolumab in Melanoma,A Phase 4 Study of Nivolumab for the Treatment of Melanoma,Observational,Phase 4,518,2020-09-09,2021-07-14,Recruiting,Industry,Crossover Assignment,Prevention,Nivolumab,Anti-PD-1,Melanoma
NCT32889601,Study of Nivolumab in Melanoma,A Phase 4 Study of Nivolumab for the Treatment of Melanoma,Interventional,Phase 4,922,2022-09-04,2022-11-19,Recruiting,Industry,Parallel Assignment,Treatment,Nivolumab,Anti-PD-1,Melanoma
NCT75925533,Study of Nivolumab in Melanoma,A Phase 4 Study of Nivolumab for the Treatment of Melanoma,Interventional,Phase 4,560,2022-01-23,2022-03-05,Completed,Other,Crossover Assignment,Diagnostic,Nivolumab,Anti-PD-1,Melanoma
NCT94198799,Study of Nivolumab in Lung Cancer,A Phase 1 Study of Nivolumab for the Treatment of Lung Cancer,Observational,Phase 1,834,2024-10-04,2026-01-31,Completed,Other,Single Group Assignment,Supportive Care,Nivolumab,Anti-PD-1,Lung Cancer
NCT73617729,Study of Nivolumab in Lung Cancer,A Phase 1 Study of Nivolumab for the Treatment of Lung Cancer,Interventional,Phase 1,762,2020-06-23,2021-01-21,Terminated,Industry,Single Group Assignment,Treatment,Nivolumab,Anti-PD-1,Lung Cancer
NCT15479368,Study of Nivolumab in Lung Cancer,A Phase 1 Study of Nivolumab for the Treatment of Lung Cancer,Observational,Phase 1,941,2021-04-09,2021-08-18,Recruiting,Industry,Crossover Assignment,Treatment,Nivolumab,Anti-PD-1,Lung Cancer
NCT97301291,Study of Nivolumab in Lung Cancer,A Phase 2 Study of Nivolumab for the Treatment of Lung Cancer,Interventional,Phase 2,929,2020-04-13,2020-07-22,Suspended,NIH,Crossover Assignment,Prevention,Nivolumab,Anti-PD-1,Lung Cancer
NCT60553499,Study of Nivolumab in Lung Cancer,A Phase 2 Study of Nivolumab for the Treatment of Lung Cancer,Observational,Phase 2,488,2022-12-18,2023-12-14,Terminated,Industry,Parallel Assignment,Treatment,Nivolumab,Anti-PD-1,Lung Cancer
NCT55268605,Study of Nivolumab in Lung Cancer,A Phase 2 Study of Nivolumab for the Treatment of Lung Cancer,Interventional,Phase 2,435,2022-10-07,2023-12-03,Suspended,Industry,Single Group Assignment,Prevention,Nivolumab,Anti-PD-1,Lung Cancer
NCT39313364,Study of Nivolumab in Lung Cancer,A Phase 3 Study of Nivolumab for the Treatment of Lung Cancer,Interventional,Phase 3,191,2023-04-13,2024-02-27,Recruiting,Other,Parallel Assignment,Diagnostic,Nivolumab,Anti-PD-1,Lung Cancer
NCT18387314,Study of Nivolumab in Lung Cancer,A Phase 3 Study of Nivolumab for the Treatment of Lung Cancer,Interventional,Phase 3,311,2020-06-28,2020-11-20,Completed,NIH,Single Group Assignment,Prevention,Nivolumab,Anti-PD-1,Lung Cancer
NCT86678181,Study of Nivolumab in Lung Cancer,A Phase 3 Study of Nivolumab for the Treatment of Lung Cancer,Interventional,Phase 3,219,2023-01-15,2023-07-09,Suspended,Industry,Crossover Assignment,Treatment,Nivolumab,Anti-PD-1,Lung Cancer
NCT75343369,Study of Nivolumab in Lung Cancer,A Phase 4 Study of Nivolumab for the Treatment of Lung Cancer,Interventional,Phase 4,978,2023-11-06,2025-09-28,Terminated,NIH,Parallel Assignment,Diagnostic,Nivolumab,Anti-PD-1,Lung Cancer
NCT42505109,Study of Nivolumab in Lung Cancer,A Phase 4 Study of Nivolumab for the Treatment of Lung Cancer,Interventional,Phase 4,904,2020-03-06,2020-07-04,Terminated,NIH,Crossover Assignment,Supportive Care,Nivolumab,Anti-PD-1,Lung Cancer
NCT62260047,Study of Nivolumab in Lung Cancer,A Phase 4 Study of Nivolumab for the Treatment of Lung Cancer,Interventional,Phase 4,948,2021-01-01,2022-01-23,Terminated,Other,Parallel Assignment,Supportive Care,Nivolumab,Anti-PD-1,Lung Cancer
NCT80938625,Study of Nivolumab in Lymphoma,A Phase 1 Study of Nivolumab for the Treatment of Lymphoma,Interventional,Phase 1,555,2022-01-01,2022-02-13,Terminated,Industry,Single Group Assignment,Treatment,Nivolumab,Anti-PD-1,Lymphoma
NCT77308094,Study of Nivolumab in Lymphoma,A Phase 1 Study of Nivolumab for the Treatment of Lymphoma,Interventional,Phase 1,626,2024-03-08,2025-10-15,Suspended,NIH,Parallel Assignment,Treatment,Nivolumab,Anti-PD-1,Lymphoma
NCT90762726,Study of Nivolumab in Lymphoma,A Phase 1 Study of Nivolumab for the Treatment of Lymphoma,Observational,Phase 1,525,2024-05-10,2026-03-31,Recruiting,Other,Crossover Assignment,Diagnostic,Nivolumab,Anti-PD-1,Lymphoma
NCT76046465,Study of Nivolumab in Lymphoma,A Phase 2 Study of Nivolumab for the Treatment of Lymphoma,Observational,Phase 2,724,2021-10-30,2022-03-04,Suspended,Industry,Single Group Assignment,Supportive Care,Nivolumab,Anti-PD-1,Lymphoma
NCT78929451,Study of Nivolumab in Lymphoma,A Phase 2 Study of Nivolumab for the Treatment of Lymphoma,Observational,Phase 2,596,2022-09-13,2023-07-31,Recruiting,Other,Single Group Assignment,Diagnostic,Nivolumab,Anti-PD-1,Lymphoma
NCT16638362,Study of Nivolumab in Lymphoma,A Phase 2 Study of Nivolumab for the Treatment of Lymphoma,Observational,Phase 2,926,2022-05-28,2023-09-14,Suspended,NIH,Parallel Assignment,Prevention,Nivolumab,Anti-PD-1,Lymphoma
NCT87218069,Study of Nivolumab in Lymphoma,A Phase 3 Study of Nivolumab for the Treatment of Lymphoma,Observational,Phase 3,504,2021-01-09,2023-01-02,Suspended,NIH,Crossover Assignment,Supportive Care,Nivolumab,Anti-PD-1,Lymphoma
NCT85275764,Study of Nivolumab in Lymphoma,A Phase 3 Study of Nivolumab for the Treatment of Lymphoma,Observational,Phase 3,104,2021-02-21,2021-11-09,Completed,Other,Single Group Assignment,Treatment,Nivolumab,Anti-PD-1,Lymphoma
NCT64596365,Study of Nivolumab in Lymphoma,A Phase 3 Study of Nivolumab for the Treatment of Lymphoma,Interventional,Phase 3,253,2022-04-13,2022-06-04,Recruiting,NIH,Crossover Assignment,Prevention,Nivolumab,Anti-PD-1,Lymphoma
NCT81751883,Study of Nivolumab in Lymphoma,A Phase 4 Study of Nivolumab for the Treatment of Lymphoma,Interventional,Phase 4,227,2024-02-24,2024-08-15,Terminated,Other,Crossover Assignment,Treatment,Nivolumab,Anti-PD-1,Lymphoma
NCT58789817,Study of Nivolumab in Lymphoma,A Phase 4 Study of Nivolumab for the Treatment of Lymphoma,Observational,Phase 4,409,2024-09-14,2025-01-09,Completed,NIH,Parallel Assignment,Supportive Care,Nivolumab,Anti-PD-1,Lymphoma
NCT53634000,Study of Nivolumab in Lymphoma,A Phase 4 Study of Nivolumab for the Treatment of Lymphoma,Interventional,Phase 4,282,2022-04-11,2023-11-08,Suspended,Other,Parallel Assignment,Treatment,Nivolumab,Anti-PD-1,Lymphoma
NCT90878202,Study of Cemiplimab in Melanoma,A Phase 1 Study of Cemiplimab for the Treatment of Melanoma,Interventional,Phase 1,939,2025-04-20,2026-09-03,Suspended,Industry,Crossover Assignment,Prevention,Cemiplimab,Anti-PD-1,Melanoma
NCT53849951,Study of Cemiplimab in Melanoma,A Phase 1 Study of Cemiplimab for the Treatment of Melanoma,Observational,Phase 1,682,2022-01-22,2022-08-24,Completed,Other,Single Group Assignment,Treatment,Cemiplimab,Anti-PD-1,Melanoma
NCT41906780,Study of Cemiplimab in Melanoma,A Phase 2 Study of Cemiplimab for the Treatment of Melanoma,Interventional,Phase 2,553,2025-01-29,2026-05-24,Completed,Industry,Parallel Assignment,Prevention,Cemiplimab,Anti-PD-1,Melanoma
NCT15135495,Study of Cemiplimab in Melanoma,A Phase 2 Study of Cemiplimab for the Treatment of Melanoma,Interventional,Phase 2,326,2024-06-17,2026-06-04,Terminated,Other,Parallel Assignment,Treatment,Cemiplimab,Anti-PD-1,Melanoma
NCT17616763,Study of Cemiplimab in Melanoma,A Phase 2 Study of Cemiplimab for the Treatment of Melanoma,Observational,Phase 2,437,2025-03-25,2026-04-09,Recruiting,Other,Crossover Assignment,Supportive Care,Cemiplimab,Anti-PD-1,Melanoma
NCT90088890,Study of Cemiplimab in Melanoma,A Phase 3 Study of Cemiplimab for the Treatment of Melanoma,Observational,Phase 3,391,2024-02-23,2025-06-28,Terminated,Industry,Crossover Assignment,Diagnostic,Cemiplimab,Anti-PD-1,Melanoma
NCT66786008,Study of Cemiplimab in Melanoma,A Phase 3 Study of Cemiplimab for the Treatment of Melanoma,Interventional,Phase 3,973,2020-06-13,2022-05-01,Suspended,NIH,Parallel Assignment,Treatment,Cemiplimab,Anti-PD-1,Melanoma
NCT16562248,Study of Cemiplimab in Melanoma,A Phase 3 Study of Cemiplimab for the Treatment of Melanoma,Observational,Phase 3,239,2023-06-20,2024-06-14,Terminated,Industry,Parallel Assignment,Supportive Care,Cemiplimab,Anti-PD-1,Melanoma
NCT47901988,Study of Cemiplimab in Melanoma,A Phase 4 Study of Cemiplimab for the Treatment of Melanoma,Observational,Phase 4,548,2021-08-20,2022-08-26,Suspended,Other,Single Group Assignment,Diagnostic,Cemiplimab,Anti-PD-1,Melanoma
NCT58062277,Study of Cemiplimab in Melanoma,A Phase 4 Study of Cemiplimab for the Treatment of Melanoma,Observational,Phase 4,474,2023-07-06,2024-10-30,Completed,Industry,Crossover Assignment,Diagnostic,Cemiplimab,Anti-PD-1,Melanoma
NCT65516625,Study of Cemiplimab in Melanoma,A Phase 4 Study of Cemiplimab for the Treatment of Melanoma,Observational,Phase 4,693,2023-12-03,2024-12-07,Suspended,Other,Parallel Assignment,Prevention,Cemiplimab,Anti-PD-1,Melanoma
NCT29084518,Study of Cemiplimab in Lung Cancer,A Phase 1 Study of Cemiplimab for the Treatment of Lung Cancer,Observational,Phase 1,846,2023-09-21,2024-02-09,Suspended,NIH,Crossover Assignment,Supportive Care,Cemiplimab,Anti-PD-1,Lung Cancer
NCT44253125,Study of Cemiplimab in Lung Cancer,A Phase 1 Study of Cemiplimab for the Treatment of Lung Cancer,Observational,Phase 1,359,2024-12-04,2026-01-05,Terminated,Industry,Crossover Assignment,Diagnostic,Cemiplimab,Anti-PD-1,Lung Cancer
NCT25404073,Study of Cemiplimab in Lung Cancer,A Phase 2 Study of Cemiplimab for the Treatment of Lung Cancer,Observational,Phase 2,475,2020-12-13,2021-10-01,Terminated,NIH,Single Group Assignment,Supportive Care,Cemiplimab,Anti-PD-1,Lung Cancer
NCT68692331,Study of Cemiplimab in Lung Cancer,A Phase 2 Study of Cemiplimab for the Treatment of Lung Cancer,Interventional,Phase 2,779,2024-03-19,2025-03-27,Completed,NIH,Single Group Assignment,Treatment,Cemiplimab,Anti-PD-1,Lung Cancer
NCT73424244,Study of Cemiplimab in Lung Cancer,A Phase 2 Study of Cemiplimab for the Treatment of Lung Cancer,Observational,Phase 2,306,2021-10-21,2022-02-27,Suspended,Industry,Crossover Assignment,Supportive Care,Cemiplimab,Anti-PD-1,Lung Cancer
NCT41033207,Study of Cemiplimab in Lung Cancer,A Phase 3 Study of Cemiplimab for the Treatment of Lung Cancer,Interventional,Phase 3,57,2020-05-29,2022-01-29,Completed,Other,Parallel Assignment,Prevention,Cemiplimab,Anti-PD-1,Lung Cancer
NCT12959918,Study of Cemiplimab in Lung Cancer,A Phase 3 Study of Cemiplimab for the Treatment of Lung Cancer,Interventional,Phase 3,819,2022-07-22,2023-06-21,Recruiting,Other,Single Group Assignment,Prevention,Cemiplimab,Anti-PD-1,Lung Cancer
NCT24693985,Study of Cemiplimab in Lung Cancer,A Phase 3 Study of Cemiplimab for the Treatment of Lung Cancer,Interventional,Phase 3,448,2024-09-05,2025-09-05,Completed,Industry,Single Group Assignment,Supportive Care,Cemiplimab,Anti-PD-1,Lung Cancer
NCT54177517,Study of Cemiplimab in Lung Cancer,A Phase 4 Study of Cemiplimab for the Treatment of Lung Cancer,Interventional,Phase 4,426,2024-05-20,2025-08-07,Recruiting,NIH,Crossover Assignment,Supportive Care,Cemiplimab,Anti-PD-1,Lung Cancer
NCT63485508,Study of Cemiplimab in Lung Cancer,A Phase 4 Study of Cemiplimab for the Treatment of Lung Cancer,Interventional,Phase 4,686,2024-12-04,2025-03-03,Completed,Industry,Parallel Assignment,Prevention,Cemiplimab,Anti-PD-1,Lung Cancer
NCT12530506,Study of Cemiplimab in Lymphoma,A Phase 1 Study of Cemiplimab for the Treatment of Lymphoma,Interventional,Phase 1,803,2023-04-26,2025-03-22,Completed,NIH,Crossover Assignment,Diagnostic,Cemiplimab,Anti-PD-1,Lymphoma
NCT72297871,Study of Cemiplimab in Lymphoma,A Phase 1 Study of Cemiplimab for the Treatment of Lymphoma,Interventional,Phase 1,153,2021-01-24,2022-11-16,Recruiting,Industry,Parallel Assignment,Treatment,Cemiplimab,Anti-PD-1,Lymphoma
NCT24136200,Study of Cemiplimab in Lymphoma,A Phase 1 Study of Cemiplimab for the Treatment of Lymphoma,Interventional,Phase 1,70,2020-12-12,2022-06-11,Terminated,Industry,Parallel Assignment,Diagnostic,Cemiplimab,Anti-PD-1,Lymphoma
NCT21710226,Study of Cemiplimab in Lymphoma,A Phase 2 Study of Cemiplimab for the Treatment of Lymphoma,Observational,Phase 2,495,2023-06-10,2024-12-28,Completed,Industry,Single Group Assignment,Prevention,Cemiplimab,Anti-PD-1,Lymphoma
NCT39801497,Study of Cemiplimab in Lymphoma,A Phase 2 Study of Cemiplimab for the Treatment of Lymphoma,Interventional,Phase 2,27,2021-07-12,2022-02-04,Terminated,Industry,Crossover Assignment,Treatment,Cemiplimab,Anti-PD-1,Lymphoma
NCT67291114,Study of Cemiplimab in Lymphoma,A Phase 3 Study of Cemiplimab for the Treatment of Lymphoma,Observational,Phase 3,480,2025-02-17,2026-12-28,Suspended,Other,Crossover Assignment,Prevention,Cemiplimab,Anti-PD-1,Lymphoma
NCT87668614,Study of Cemiplimab in Lymphoma,A Phase 3 Study of Cemiplimab for the Treatment of Lymphoma,Interventional,Phase 3,347,2020-06-29,2021-03-08,Completed,NIH,Crossover Assignment,Prevention,Cemiplimab,Anti-PD-1,Lymphoma
NCT25829882,Study of Cemiplimab in Lymphoma,A Phase 4 Study of Cemiplimab for the Treatment of Lymphoma,Observational,Phase 4,530,2023-06-21,2025-01-12,Recruiting,NIH,Parallel Assignment,Diagnostic,Cemiplimab,Anti-PD-1,Lymphoma
NCT33583694,Study of Atezolizumab in Lung Cancer,A Phase 1 Study of Atezolizumab for the Treatment of Lung Cancer,Observational,Phase 1,527,2022-04-25,2023-06-27,Recruiting,NIH,Crossover Assignment,Supportive Care,Atezolizumab,Anti-PD-L1,Lung Cancer
NCT46034490,Study of Atezolizumab in Lung Cancer,A Phase 1 Study of Atezolizumab for the Treatment of Lung Cancer,Interventional,Phase 1,784,2024-09-07,2025-06-14,Suspended,Industry,Crossover Assignment,Supportive Care,Atezolizumab,Anti-PD-L1,Lung Cancer
NCT66716385,Study of Atezolizumab in Lung Cancer,A Phase 1 Study of Atezolizumab for the Treatment of Lung Cancer,Observational,Phase 1,259,2023-03-21,2025-02-04,Terminated,NIH,Parallel Assignment,Prevention,Atezolizumab,Anti-PD-L1,Lung Cancer
NCT65899919,Study of Atezolizumab in Lung Cancer,A Phase 2 Study of Atezolizumab for the Treatment of Lung Cancer,Observational,Phase 2,420,2023-09-28,2024-12-30,Completed,Industry,Parallel Assignment,Diagnostic,Atezolizumab,Anti-PD-L1,Lung Cancer
NCT80575300,Study of Atezolizumab in Lung Cancer,A Phase 2 Study of Atezolizumab for the Treatment of Lung Cancer,Interventional,Phase 2,426,2020-08-30,2021-09-22,Suspended,Other,Crossover Assignment,Diagnostic,Atezolizumab,Anti-PD-L1,Lung Cancer
NCT75681869,Study of Atezolizumab in Lung Cancer,A Phase 3 Study of Atezolizumab for the Treatment of Lung Cancer,Interventional,Phase 3,552,2021-11-14,2022-09-05,Completed,Industry,Single Group Assignment,Diagnostic,Atezolizumab,Anti-PD-L1,Lung Cancer
NCT96504389,Study of Atezolizumab in Lung Cancer,A Phase 4 Study of Atezolizumab for the Treatment of Lung Cancer,Interventional,Phase 4,541,2024-06-22,2025-08-15,Recruiting,NIH,Parallel Assignment,Diagnostic,Atezolizumab,Anti-PD-L1,Lung Cancer
NCT46042865,Study of Atezolizumab in Bladder Cancer,A Phase 1 Study of Atezolizumab for the Treatment of Bladder Cancer,Interventional,Phase 1,372,2021-10-25,2022-01-11,Suspended,Industry,Single Group Assignment,Diagnostic,Atezolizumab,Anti-PD-L1,Bladder Cancer
NCT64054453,Study of Atezolizumab in Bladder Cancer,A Phase 1 Study of Atezolizumab for the Treatment of Bladder Cancer,Interventional,Phase 1,379,2021-08-13,2023-02-22,Completed,NIH,Parallel Assignment,Treatment,Atezolizumab,Anti-PD-L1,Bladder Cancer
NCT99658277,Study of Atezolizumab in Bladder Cancer,A Phase 1 Study of Atezolizumab for the Treatment of Bladder Cancer,Observational,Phase 1,502,2023-12-04,2024-05-26,Terminated,Other,Parallel Assignment,Supportive Care,Atezolizumab,Anti-PD-L1,Bladder Cancer
NCT88131226,Study of Atezolizumab in Bladder Cancer,A Phase 2 Study of Atezolizumab for the Treatment of Bladder Cancer,Interventional,Phase 2,913,2021-04-04,2022-09-18,Recruiting,Other,Crossover Assignment,Prevention,Atezolizumab,Anti-PD-L1,Bladder Cancer
NCT56751684,Study of Atezolizumab in Bladder Cancer,A Phase 2 Study of Atezolizumab for the Treatment of Bladder Cancer,Interventional,Phase 2,117,2023-06-11,2025-02-04,Recruiting,Industry,Single Group Assignment,Prevention,Atezolizumab,Anti-PD-L1,Bladder Cancer
NCT91343847,Study of Atezolizumab in Bladder Cancer,A Phase 2 Study of Atezolizumab for the Treatment of Bladder Cancer,Observational,Phase 2,85,2024-12-16,2025-07-02,Terminated,NIH,Crossover Assignment,Treatment,Atezolizumab,Anti-PD-L1,Bladder Cancer
NCT98559134,Study of Atezolizumab in Bladder Cancer,A Phase 3 Study of Atezolizumab for the Treatment of Bladder Cancer,Interventional,Phase 3,565,2023-04-02,2023-11-09,Recruiting,NIH,Parallel Assignment,Treatment,Atezolizumab,Anti-PD-L1,Bladder Cancer
NCT70109965,Study of Atezolizumab in Bladder Cancer,A Phase 4 Study of Atezolizumab for the Treatment of Bladder Cancer,Interventional,Phase 4,871,2023-12-18,2024-12-06,Terminated,Other,Parallel Assignment,Treatment,Atezolizumab,Anti-PD-L1,Bladder Cancer
NCT75862657,Study of Atezolizumab in Breast Cancer,A Phase 1 Study of Atezolizumab for the Treatment of Breast Cancer,Interventional,Phase 1,229,2023-05-01,2024-11-28,Terminated,NIH,Crossover Assignment,Supportive Care,Atezolizumab,Anti-PD-L1,Breast Cancer
NCT76824808,Study of Atezolizumab in Breast Cancer,A Phase 2 Study of Atezolizumab for the Treatment of Breast Cancer,Interventional,Phase 2,152,2022-03-23,2023-02-06,Suspended,Other,Crossover Assignment,Supportive Care,Atezolizumab,Anti-PD-L1,Breast Cancer
NCT25629315,Study of Atezolizumab in Breast Cancer,A Phase 2 Study of Atezolizumab for the Treatment of Breast Cancer,Interventional,Phase 2,21,2021-10-02,2023-05-07,Suspended,NIH,Parallel Assignment,Prevention,Atezolizumab,Anti-PD-L1,Breast Cancer
NCT32803597,Study of Atezolizumab in Breast Cancer,A Phase 2 Study of Atezolizumab for the Treatment of Breast Cancer,Observational,Phase 2,955,2020-05-13,2021-12-13,Terminated,NIH,Parallel Assignment,Diagnostic,Atezolizumab,Anti-PD-L1,Breast Cancer
NCT67098592,Study of Atezolizumab in Breast Cancer,A Phase 3 Study of Atezolizumab for the Treatment of Breast Cancer,Observational,Phase 3,849,2024-10-11,2025-10-13,Suspended,Industry,Single Group Assignment,Diagnostic,Atezolizumab,Anti-PD-L1,Breast Cancer
NCT88982673,Study of Atezolizumab in Breast Cancer,A Phase 4 Study of Atezolizumab for the Treatment of Breast Cancer,Interventional,Phase 4,934,2025-02-11,2026-11-18,Completed,Industry,Parallel Assignment,Treatment,Atezolizumab,Anti-PD-L1,Breast Cancer
NCT73325873,Study of Atezolizumab in Breast Cancer,A Phase 4 Study of Atezolizumab for the Treatment of Breast Cancer,Interventional,Phase 4,854,2020-08-29,2022-06-14,Recruiting,NIH,Parallel Assignment,Supportive Care,Atezolizumab,Anti-PD-L1,Breast Cancer
NCT69726904,Study of Durvalumab in Lung Cancer,A Phase 1 Study of Durvalumab for the Treatment of Lung Cancer,Observational,Phase 1,419,2023-09-21,2023-10-26,Recruiting,Other,Parallel Assignment,Treatment,Durvalumab,Anti-PD-L1,Lung Cancer
NCT53036638,Study of Durvalumab in Lung Cancer,A Phase 1 Study of Durvalumab for the Treatment of Lung Cancer,Observational,Phase 1,345,2024-03-02,2024-09-27,Completed,NIH,Single Group Assignment,Prevention,Durvalumab,Anti-PD-L1,Lung Cancer
NCT85353811,Study of Durvalumab in Lung Cancer,A Phase 1 Study of Durvalumab for the Treatment of Lung Cancer,Interventional,Phase 1,541,2020-10-28,2022-04-18,Completed,Other,Crossover Assignment,Supportive Care,Durvalumab,Anti-PD-L1,Lung Cancer
NCT21304959,Study of Durvalumab in Lung Cancer,A Phase 2 Study of Durvalumab for the Treatment of Lung Cancer,Observational,Phase 2,888,2022-02-01,2023-03-14,Completed,Other,Parallel Assignment,Diagnostic,Durvalumab,Anti-PD-L1,Lung Cancer
NCT77829873,Study of Durvalumab in Lung Cancer,A Phase 3 Study of Durvalumab for the Treatment of Lung Cancer,Observational,Phase 3,899,2023-12-30,2024-05-02,Suspended,Other,Crossover Assignment,Prevention,Durvalumab,Anti-PD-L1,Lung Cancer
NCT29437925,Study of Durvalumab in Lung Cancer,A Phase 3 Study of Durvalumab for the Treatment of Lung Cancer,Observational,Phase 3,616,2020-03-21,2021-12-17,Completed,NIH,Single Group Assignment,Prevention,Durvalumab,Anti-PD-L1,Lung Cancer
NCT98990326,Study of Durvalumab in Lung Cancer,A Phase 4 Study of Durvalumab for the Treatment of Lung Cancer,Observational,Phase 4,529,2022-11-04,2023-04-17,Suspended,Industry,Crossover Assignment,Diagnostic,Durvalumab,Anti-PD-L1,Lung Cancer
NCT62312552,Study of Durvalumab in Lung Cancer,A Phase 4 Study of Durvalumab for the Treatment of Lung Cancer,Interventional,Phase 4,83,2020-04-03,2021-12-23,Suspended,Other,Parallel Assignment,Treatment,Durvalumab,Anti-PD-L1,Lung Cancer
NCT10860513,Study of Durvalumab in Bladder Cancer,A Phase 1 Study of Durvalumab for the Treatment of Bladder Cancer,Observational,Phase 1,102,2023-09-25,2025-09-13,Terminated,Industry,Parallel Assignment,Supportive Care,Durvalumab,Anti-PD-L1,Bladder Cancer
NCT65333032,Study of Durvalumab in Bladder Cancer,A Phase 2 Study of Durvalumab for the Treatment of Bladder Cancer,Observational,Phase 2,871,2022-06-06,2022-12-27,Completed,Other,Parallel Assignment,Diagnostic,Durvalumab,Anti-PD-L1,Bladder Cancer
NCT70836974,Study of Durvalumab in Bladder Cancer,A Phase 3 Study of Durvalumab for the Treatment of Bladder Cancer,Interventional,Phase 3,352,2025-01-13,2026-05-17,Completed,Industry,Single Group Assignment,Prevention,Durvalumab,Anti-PD-L1,Bladder Cancer
NCT50158543,Study of Durvalumab in Bladder Cancer,A Phase 4 Study of Durvalumab for the Treatment of Bladder Cancer,Interventional,Phase 4,721,2020-12-06,2022-06-09,Terminated,Other,Single Group Assignment,Treatment,Durvalumab,Anti-PD-L1,Bladder Cancer
NCT16316498,Study of Durvalumab in Bladder Cancer,A Phase 4 Study of Durvalumab for the Treatment of Bladder Cancer,Observational,Phase 4,795,2022-07-10,2023-12-18,Recruiting,NIH,Single Group Assignment,Prevention,Durvalumab,Anti-PD-L1,Bladder Cancer
NCT99530343,Study of Durvalumab in Bladder Cancer,A Phase 4 Study of Durvalumab for the Treatment of Bladder Cancer,Interventional,Phase 4,398,2021-05-10,2023-01-27,Suspended,NIH,Single Group Assignment,Supportive Care,Durvalumab,Anti-PD-L1,Bladder Cancer
NCT58137453,Study of Durvalumab in Breast Cancer,A Phase 1 Study of Durvalumab for the Treatment of Breast Cancer,Interventional,Phase 1,584,2021-08-28,2022-12-12,Terminated,NIH,Crossover Assignment,Diagnostic,Durvalumab,Anti-PD-L1,Breast Cancer
NCT44823892,Study of Durvalumab in Breast Cancer,A Phase 2 Study of Durvalumab for the Treatment of Breast Cancer,Interventional,Phase 2,248,2023-11-25,2025-03-07,Recruiting,Industry,Crossover Assignment,Treatment,Durvalumab,Anti-PD-L1,Breast Cancer
NCT51078860,Study of Durvalumab in Breast Cancer,A Phase 3 Study of Durvalumab for the Treatment of Breast Cancer,Observational,Phase 3,701,2022-08-09,2024-05-17,Terminated,NIH,Parallel Assignment,Supportive Care,Durvalumab,Anti-PD-L1,Breast Cancer
NCT55975214,Study of Durvalumab in Breast Cancer,A Phase 3 Study of Durvalumab for the Treatment of Breast Cancer,Interventional,Phase 3,563,2022-02-03,2023-12-08,Completed,Other,Parallel Assignment,Diagnostic,Durvalumab,Anti-PD-L1,Breast Cancer
NCT34466698,Study of Durvalumab in Breast Cancer,A Phase 4 Study of Durvalumab for the Treatment of Breast Cancer,Interventional,Phase 4,944,2025-04-20,2027-04-09,Recruiting,NIH,Crossover Assignment,Prevention,Durvalumab,Anti-PD-L1,Breast Cancer
NCT27298431,Study of Avelumab in Lung Cancer,A Phase 1 Study of Avelumab for the Treatment of Lung Cancer,Interventional,Phase 1,964,2020-02-28,2021-07-24,Recruiting,Other,Crossover Assignment,Prevention,Avelumab,Anti-PD-L1,Lung Cancer
NCT65573035,Study of Avelumab in Lung Cancer,A Phase 1 Study of Avelumab for the Treatment of Lung Cancer,Interventional,Phase 1,291,2025-04-04,2027-01-28,Suspended,Other,Single Group Assignment,Supportive Care,Avelumab,Anti-PD-L1,Lung Cancer
NCT80442267,Study of Avelumab in Lung Cancer,A Phase 1 Study of Avelumab for the Treatment of Lung Cancer,Interventional,Phase 1,323,2023-08-08,2024-06-20,Completed,Industry,Parallel Assignment,Treatment,Avelumab,Anti-PD-L1,Lung Cancer
NCT63997255,Study of Avelumab in Lung Cancer,A Phase 2 Study of Avelumab for the Treatment of Lung Cancer,Observational,Phase 2,835,2023-03-13,2024-10-03,Terminated,NIH,Parallel Assignment,Treatment,Avelumab,Anti-PD-L1,Lung Cancer
NCT48832433,Study of Avelumab in Lung Cancer,A Phase 3 Study of Avelumab for the Treatment of Lung Cancer,Interventional,Phase 3,654,2020-02-28,2020-11-11,Terminated,Other,Crossover Assignment,Treatment,Avelumab,Anti-PD-L1,Lung Cancer
NCT58719623,Study of Avelumab in Lung Cancer,A Phase 3 Study of Avelumab for the Treatment of Lung Cancer,Observational,Phase 3,102,2022-03-12,2022-04-27,Terminated,Industry,Parallel Assignment,Supportive Care,Avelumab,Anti-PD-L1,Lung Cancer
NCT14177472,Study of Avelumab in Lung Cancer,A Phase 4 Study of Avelumab for the Treatment of Lung Cancer,Observational,Phase 4,853,2023-11-17,2024-06-18,Completed,NIH,Parallel Assignment,Diagnostic,Avelumab,Anti-PD-L1,Lung Cancer
NCT42918888,Study of Avelumab in Lung Cancer,A Phase 4 Study of Avelumab for the Treatment of Lung Cancer,Observational,Phase 4,145,2024-08-19,2024-11-15,Suspended,Other,Parallel Assignment,Diagnostic,Avelumab,Anti-PD-L1,Lung Cancer
NCT29118784,Study of Avelumab in Bladder Cancer,A Phase 1 Study of Avelumab for the Treatment of Bladder Cancer,Interventional,Phase 1,640,2023-12-17,2025-06-10,Recruiting,NIH,Parallel Assignment,Treatment,Avelumab,Anti-PD-L1,Bladder Cancer
NCT12332652,Study of Avelumab in Bladder Cancer,A Phase 1 Study of Avelumab for the Treatment of Bladder Cancer,Interventional,Phase 1,283,2022-02-11,2023-06-30,Suspended,Other,Single Group Assignment,Treatment,Avelumab,Anti-PD-L1,Bladder Cancer
NCT72626465,Study of Avelumab in Bladder Cancer,A Phase 1 Study of Avelumab for the Treatment of Bladder Cancer,Observational,Phase 1,995,2021-06-02,2022-02-24,Terminated,Industry,Single Group Assignment,Treatment,Avelumab,Anti-PD-L1,Bladder Cancer
NCT88737941,Study of Avelumab in Bladder Cancer,A Phase 2 Study of Avelumab for the Treatment of Bladder Cancer,Interventional,Phase 2,530,2020-03-07,2022-02-02,Suspended,Other,Crossover Assignment,Diagnostic,Avelumab,Anti-PD-L1,Bladder Cancer
NCT25662679,Study of Avelumab in Bladder Cancer,A Phase 2 Study of Avelumab for the Treatment of Bladder Cancer,Interventional,Phase 2,437,2025-04-21,2026-03-17,Recruiting,Other,Crossover Assignment,Supportive Care,Avelumab,Anti-PD-L1,Bladder Cancer
NCT60509361,Study of Avelumab in Bladder Cancer,A Phase 2 Study of Avelumab for the Treatment of Bladder Cancer,Observational,Phase 2,795,2022-02-15,2023-06-14,Recruiting,Other,Parallel Assignment,Treatment,Avelumab,Anti-PD-L1,Bladder Cancer
NCT49720492,Study of Avelumab in Bladder Cancer,A Phase 3 Study of Avelumab for the Treatment of Bladder Cancer,Observational,Phase 3,222,2024-10-07,2026-03-08,Recruiting,NIH,Parallel Assignment,Diagnostic,Avelumab,Anti-PD-L1,Bladder Cancer
NCT40175824,Study of Avelumab in Bladder Cancer,A Phase 3 Study of Avelumab for the Treatment of Bladder Cancer,Interventional,Phase 3,989,2022-07-04,2022-12-01,Completed,Other,Crossover Assignment,Supportive Care,Avelumab,Anti-PD-L1,Bladder Cancer
NCT59769233,Study of Avelumab in Bladder Cancer,A Phase 4 Study of Avelumab for the Treatment of Bladder Cancer,Interventional,Phase 4,896,2023-10-27,2024-09-14,Recruiting,Industry,Parallel Assignment,Prevention,Avelumab,Anti-PD-L1,Bladder Cancer
NCT57904088,Study of Avelumab in Breast Cancer,A Phase 1 Study of Avelumab for the Treatment of Breast Cancer,Interventional,Phase 1,797,2025-03-12,2026-03-02,Recruiting,Other,Crossover Assignment,Treatment,Avelumab,Anti-PD-L1,Breast Cancer
NCT46535339,Study of Avelumab in Breast Cancer,A Phase 2 Study of Avelumab for the Treatment of Breast Cancer,Observational,Phase 2,183,2021-01-30,2021-04-16,Completed,NIH,Parallel Assignment,Treatment,Avelumab,Anti-PD-L1,Breast Cancer
NCT89225649,Study of Avelumab in Breast Cancer,A Phase 2 Study of Avelumab for the Treatment of Breast Cancer,Interventional,Phase 2,879,2021-09-13,2023-07-06,Suspended,Industry,Parallel Assignment,Supportive Care,Avelumab,Anti-PD-L1,Breast Cancer
NCT59440678,Study of Avelumab in Breast Cancer,A Phase 2 Study of Avelumab for the Treatment of Breast Cancer,Interventional,Phase 2,61,2020-11-03,2021-09-13,Terminated,Other,Single Group Assignment,Treatment,Avelumab,Anti-PD-L1,Breast Cancer
NCT37505588,Study of Avelumab in Breast Cancer,A Phase 3 Study of Avelumab for the Treatment of Breast Cancer,Observational,Phase 3,497,2023-05-24,2025-04-12,Completed,Other,Crossover Assignment,Prevention,Avelumab,Anti-PD-L1,Breast Cancer
NCT24133250,Study of Avelumab in Breast Cancer,A Phase 4 Study of Avelumab for the Treatment of Breast Cancer,Interventional,Phase 4,402,2021-02-26,2022-04-24,Completed,NIH,Parallel Assignment,Supportive Care,Avelumab,Anti-PD-L1,Breast Cancer
NCT33373656,Study of Ipilimumab in Melanoma,A Phase 1 Study of Ipilimumab for the Treatment of Melanoma,Observational,Phase 1,584,2024-02-20,2024-06-26,Completed,NIH,Parallel Assignment,Supportive Care,Ipilimumab,Anti-CTLA-4,Melanoma
NCT97104381,Study of Ipilimumab in Melanoma,A Phase 1 Study of Ipilimumab for the Treatment of Melanoma,Observational,Phase 1,514,2021-04-03,2021-05-12,Suspended,NIH,Crossover Assignment,Treatment,Ipilimumab,Anti-CTLA-4,Melanoma
NCT11931862,Study of Ipilimumab in Melanoma,A Phase 2 Study of Ipilimumab for the Treatment of Melanoma,Observational,Phase 2,873,2022-01-20,2023-07-10,Suspended,Industry,Crossover Assignment,Supportive Care,Ipilimumab,Anti-CTLA-4,Melanoma
NCT87230481,Study of Ipilimumab in Melanoma,A Phase 2 Study of Ipilimumab for the Treatment of Melanoma,Interventional,Phase 2,365,2024-01-15,2025-11-14,Recruiting,Other,Single Group Assignment,Diagnostic,Ipilimumab,Anti-CTLA-4,Melanoma
NCT16335321,Study of Ipilimumab in Melanoma,A Phase 3 Study of Ipilimumab for the Treatment of Melanoma,Observational,Phase 3,965,2021-07-31,2022-03-25,Recruiting,NIH,Parallel Assignment,Treatment,Ipilimumab,Anti-CTLA-4,Melanoma
NCT28519311,Study of Ipilimumab in Melanoma,A Phase 3 Study of Ipilimumab for the Treatment of Melanoma,Observational,Phase 3,479,2020-06-26,2021-12-02,Completed,Other,Single Group Assignment,Supportive Care,Ipilimumab,Anti-CTLA-4,Melanoma
NCT27084854,Study of Ipilimumab in Melanoma,A Phase 4 Study of Ipilimumab for the Treatment of Melanoma,Interventional,Phase 4,789,2021-03-09,2021-06-27,Recruiting,Industry,Crossover Assignment,Diagnostic,Ipilimumab,Anti-CTLA-4,Melanoma
NCT64768987,Study of Ipilimumab in Lung Cancer,A Phase 1 Study of Ipilimumab for the Treatment of Lung Cancer,Interventional,Phase 1,647,2021-12-18,2022-10-09,Completed,Other,Crossover Assignment,Treatment,Ipilimumab,Anti-CTLA-4,Lung Cancer
NCT92322273,Study of Ipilimumab in Lung Cancer,A Phase 1 Study of Ipilimumab for the Treatment of Lung Cancer,Observational,Phase 1,851,2023-05-19,2024-11-03,Recruiting,NIH,Single Group Assignment,Diagnostic,Ipilimumab,Anti-CTLA-4,Lung Cancer
NCT90382262,Study of Ipilimumab in Lung Cancer,A Phase 2 Study of Ipilimumab for the Treatment of Lung Cancer,Observational,Phase 2,576,2024-07-25,2024-11-19,Suspended,Industry,Parallel Assignment,Supportive Care,Ipilimumab,Anti-CTLA-4,Lung Cancer
NCT50643016,Study of Ipilimumab in Lung Cancer,A Phase 2 Study of Ipilimumab for the Treatment of Lung Cancer,Interventional,Phase 2,332,2022-03-03,2022-10-07,Recruiting,NIH,Parallel Assignment,Diagnostic,Ipilimumab,Anti-CTLA-4,Lung Cancer
NCT60442511,Study of Ipilimumab in Lung Cancer,A Phase 3 Study of Ipilimumab for the Treatment of Lung Cancer,Interventional,Phase 3,244,2021-02-12,2021-10-27,Suspended,Industry,Parallel Assignment,Prevention,Ipilimumab,Anti-CTLA-4,Lung Cancer
NCT37231699,Study of Ipilimumab in Lung Cancer,A Phase 3 Study of Ipilimumab for the Treatment of Lung Cancer,Interventional,Phase 3,422,2022-10-26,2024-10-19,Recruiting,NIH,Single Group Assignment,Prevention,Ipilimumab,Anti-CTLA-4,Lung Cancer
NCT91101049,Study of Ipilimumab in Lung Cancer,A Phase 4 Study of Ipilimumab for the Treatment of Lung Cancer,Observational,Phase 4,728,2020-04-30,2020-07-07,Terminated,Industry,Crossover Assignment,Diagnostic,Ipilimumab,Anti-CTLA-4,Lung Cancer
NCT57054706,Study of Ipilimumab in Lung Cancer,A Phase 4 Study of Ipilimumab for the Treatment of Lung Cancer,Observational,Phase 4,21,2024-07-07,2025-01-25,Terminated,NIH,Parallel Assignment,Prevention,Ipilimumab,Anti-CTLA-4,Lung Cancer
NCT78431036,Study of Tremelimumab in Melanoma,A Phase 1 Study of Tremelimumab for the Treatment of Melanoma,Observational,Phase 1,394,2023-09-02,2025-06-04,Suspended,Other,Crossover Assignment,Treatment,Tremelimumab,Anti-CTLA-4,Melanoma
NCT16337078,Study of Tremelimumab in Melanoma,A Phase 1 Study of Tremelimumab for the Treatment of Melanoma,Interventional,Phase 1,271,2021-09-25,2023-05-23,Recruiting,NIH,Parallel Assignment,Prevention,Tremelimumab,Anti-CTLA-4,Melanoma
NCT10417905,Study of Tremelimumab in Melanoma,A Phase 2 Study of Tremelimumab for the Treatment of Melanoma,Observational,Phase 2,728,2022-03-29,2022-08-27,Recruiting,Industry,Crossover Assignment,Prevention,Tremelimumab,Anti-CTLA-4,Melanoma
NCT21408995,Study of Tremelimumab in Melanoma,A Phase 2 Study of Tremelimumab for the Treatment of Melanoma,Observational,Phase 2,171,2023-01-01,2024-01-20,Recruiting,Other,Parallel Assignment,Prevention,Tremelimumab,Anti-CTLA-4,Melanoma
NCT13572258,Study of Tremelimumab in Melanoma,A Phase 2 Study of Tremelimumab for the Treatment of Melanoma,Interventional,Phase 2,725,2021-01-25,2021-09-24,Completed,Other,Single Group Assignment,Prevention,Tremelimumab,Anti-CTLA-4,Melanoma
NCT32770173,Study of Tremelimumab in Melanoma,A Phase 3 Study of Tremelimumab for the Treatment of Melanoma,Observational,Phase 3,358,2023-11-11,2025-07-01,Suspended,Other,Parallel Assignment,Treatment,Tremelimumab,Anti-CTLA-4,Melanoma
NCT97225414,Study of Tremelimumab in Melanoma,A Phase 4 Study of Tremelimumab for the Treatment of Melanoma,Interventional,Phase 4,566,2023-04-21,2024-01-03,Recruiting,Industry,Crossover Assignment,Diagnostic,Tremelimumab,Anti-CTLA-4,Melanoma
NCT41223122,Study of Tremelimumab in Melanoma,A Phase 4 Study of Tremelimumab for the Treatment of Melanoma,Observational,Phase 4,432,2020-05-27,2022-03-09,Recruiting,NIH,Parallel Assignment,Diagnostic,Tremelimumab,Anti-CTLA-4,Melanoma
NCT56265315,Study of Tremelimumab in Melanoma,A Phase 4 Study of Tremelimumab for the Treatment of Melanoma,Interventional,Phase 4,967,2021-04-24,2023-02-02,Recruiting,NIH,Crossover Assignment,Prevention,Tremelimumab,Anti-CTLA-4,Melanoma
NCT16513150,Study of Tremelimumab in Lung Cancer,A Phase 1 Study of Tremelimumab for the Treatment of Lung Cancer,Observational,Phase 1,419,2020-02-28,2021-10-24,Completed,Other,Parallel Assignment,Diagnostic,Tremelimumab,Anti-CTLA-4,Lung Cancer
NCT50986875,Study of Tremelimumab in Lung Cancer,A Phase 1 Study of Tremelimumab for the Treatment of Lung Cancer,Observational,Phase 1,688,2020-05-12,2020-11-07,Recruiting,Industry,Parallel Assignment,Diagnostic,Tremelimumab,Anti-CTLA-4,Lung Cancer
NCT54799425,Study of Tremelimumab in Lung Cancer,A Phase 1 Study of Tremelimumab for the Treatment of Lung Cancer,Interventional,Phase 1,634,2023-06-12,2024-12-03,Completed,NIH,Crossover Assignment,Diagnostic,Tremelimumab,Anti-CTLA-4,Lung Cancer
NCT89252381,Study of Tremelimumab in Lung Cancer,A Phase 2 Study of Tremelimumab for the Treatment of Lung Cancer,Observational,Phase 2,642,2020-06-04,2022-04-22,Recruiting,NIH,Parallel Assignment,Diagnostic,Tremelimumab,Anti-CTLA-4,Lung Cancer
NCT17690425,Study of Tremelimumab in Lung Cancer,A Phase 2 Study of Tremelimumab for the Treatment of Lung Cancer,Interventional,Phase 2,488,2025-03-22,2026-04-22,Terminated,Industry,Single Group Assignment,Treatment,Tremelimumab,Anti-CTLA-4,Lung Cancer
NCT79933371,Study of Tremelimumab in Lung Cancer,A Phase 2 Study of Tremelimumab for the Treatment of Lung Cancer,Observational,Phase 2,289,2022-08-30,2022-12-01,Completed,Industry,Single Group Assignment,Diagnostic,Tremelimumab,Anti-CTLA-4,Lung Cancer
NCT43887240,Study of Tremelimumab in Lung Cancer,A Phase 3 Study of Tremelimumab for the Treatment of Lung Cancer,Observational,Phase 3,249,2020-11-12,2021-01-26,Completed,Industry,Parallel Assignment,Supportive Care,Tremelimumab,Anti-CTLA-4,Lung Cancer
NCT12158858,Study of Tremelimumab in Lung Cancer,A Phase 3 Study of Tremelimumab for the Treatment of Lung Cancer,Observational,Phase 3,832,2021-08-22,2023-01-12,Suspended,Industry,Crossover Assignment,Prevention,Tremelimumab,Anti-CTLA-4,Lung Cancer
NCT33337016,Study of Tremelimumab in Lung Cancer,A Phase 3 Study of Tremelimumab for the Treatment of Lung Cancer,Observational,Phase 3,572,2021-09-27,2023-07-05,Completed,Industry,Single Group Assignment,Prevention,Tremelimumab,Anti-CTLA-4,Lung Cancer
NCT46325025,Study of Tremelimumab in Lung Cancer,A Phase 4 Study of Tremelimumab for the Treatment of Lung Cancer,Interventional,Phase 4,179,2022-02-14,2023-10-23,Completed,NIH,Single Group Assignment,Diagnostic,Tremelimumab,Anti-CTLA-4,Lung Cancer
NCT11007461,Study of Adalimumab in Rheumatoid Arthritis,A Phase 1 Study of Adalimumab for the Treatment of Rheumatoid Arthritis,Observational,Phase 1,314,2023-11-13,2024-02-23,Recruiting,Industry,Crossover Assignment,Supportive Care,Adalimumab,Anti-TNF,Rheumatoid Arthritis
NCT97748109,Study of Adalimumab in Rheumatoid Arthritis,A Phase 2 Study of Adalimumab for the Treatment of Rheumatoid Arthritis,Interventional,Phase 2,648,2023-07-13,2024-06-08,Completed,Industry,Single Group Assignment,Supportive Care,Adalimumab,Anti-TNF,Rheumatoid Arthritis
NCT35573456,Study of Adalimumab in Rheumatoid Arthritis,A Phase 2 Study of Adalimumab for the Treatment of Rheumatoid Arthritis,Observational,Phase 2,500,2021-04-22,2022-10-03,Terminated,Other,Crossover Assignment,Treatment,Adalimumab,Anti-TNF,Rheumatoid Arthritis
NCT43966690,Study of Adalimumab in Rheumatoid Arthritis,A Phase 2 Study of Adalimumab for the Treatment of Rheumatoid Arthritis,Interventional,Phase 2,649,2024-08-18,2025-05-30,Completed,NIH,Single Group Assignment,Supportive Care,Adalimumab,Anti-TNF,Rheumatoid Arthritis
NCT85933226,Study of Adalimumab in Rheumatoid Arthritis,A Phase 3 Study of Adalimumab for the Treatment of Rheumatoid Arthritis,Observational,Phase 3,929,2021-01-22,2021-09-15,Completed,NIH,Single Group Assignment,Supportive Care,Adalimumab,Anti-TNF,Rheumatoid Arthritis
NCT92756595,Study of Adalimumab in Rheumatoid Arthritis,A Phase 4 Study of Adalimumab for the Treatment of Rheumatoid Arthritis,Interventional,Phase 4,345,2020-07-12,2021-01-06,Recruiting,NIH,Crossover Assignment,Diagnostic,Adalimumab,Anti-TNF,Rheumatoid Arthritis
NCT99489167,Study of Adalimumab in Rheumatoid Arthritis,A Phase 4 Study of Adalimumab for the Treatment of Rheumatoid Arthritis,Observational,Phase 4,734,2024-02-15,2025-09-26,Suspended,Industry,Parallel Assignment,Supportive Care,Adalimumab,Anti-TNF,Rheumatoid Arthritis
NCT80682174,Study of Adalimumab in Rheumatoid Arthritis,A Phase 4 Study of Adalimumab for the Treatment of Rheumatoid Arthritis,Interventional,Phase 4,78,2025-01-11,2026-08-17,Recruiting,Other,Parallel Assignment,Prevention,Adalimumab,Anti-TNF,Rheumatoid Arthritis
NCT24135362,Study of Adalimumab in Crohn's Disease,A Phase 1 Study of Adalimumab for the Treatment of Crohn's Disease,Interventional,Phase 1,511,2021-12-07,2023-03-30,Recruiting,Other,Parallel Assignment,Treatment,Adalimumab,Anti-TNF,Crohn's Disease
NCT94038370,Study of Adalimumab in Crohn's Disease,A Phase 1 Study of Adalimumab for the Treatment of Crohn's Disease,Observational,Phase 1,126,2024-05-09,2025-04-20,Suspended,NIH,Parallel Assignment,Treatment,Adalimumab,Anti-TNF,Crohn's Disease
NCT50093936,Study of Adalimumab in Crohn's Disease,A Phase 2 Study of Adalimumab for the Treatment of Crohn's Disease,Observational,Phase 2,499,2023-04-28,2025-02-04,Suspended,Other,Parallel Assignment,Treatment,Adalimumab,Anti-TNF,Crohn's Disease
NCT48837019,Study of Adalimumab in Crohn's Disease,A Phase 2 Study of Adalimumab for the Treatment of Crohn's Disease,Observational,Phase 2,303,2022-02-06,2022-12-04,Terminated,NIH,Single Group Assignment,Treatment,Adalimumab,Anti-TNF,Crohn's Disease
NCT22311693,Study of Adalimumab in Crohn's Disease,A Phase 2 Study of Adalimumab for the Treatment of Crohn's Disease,Interventional,Phase 2,266,2020-08-17,2022-03-16,Completed,Other,Crossover Assignment,Treatment,Adalimumab,Anti-TNF,Crohn's Disease
NCT74981713,Study of Adalimumab in Crohn's Disease,A Phase 3 Study of Adalimumab for the Treatment of Crohn's Disease,Interventional,Phase 3,371,2024-09-24,2025-11-30,Terminated,Industry,Crossover Assignment,Prevention,Adalimumab,Anti-TNF,Crohn's Disease
NCT80758062,Study of Adalimumab in Crohn's Disease,A Phase 3 Study of Adalimumab for the Treatment of Crohn's Disease,Interventional,Phase 3,863,2024-03-28,2025-04-15,Suspended,Other,Parallel Assignment,Treatment,Adalimumab,Anti-TNF,Crohn's Disease
NCT80948906,Study of Adalimumab in Crohn's Disease,A Phase 4 Study of Adalimumab for the Treatment of Crohn's Disease,Interventional,Phase 4,510,2023-05-23,2024-04-23,Recruiting,NIH,Parallel Assignment,Diagnostic,Adalimumab,Anti-TNF,Crohn's Disease
NCT37486257,Study of Adalimumab in Crohn's Disease,A Phase 4 Study of Adalimumab for the Treatment of Crohn's Disease,Observational,Phase 4,433,2020-09-21,2021-06-02,Completed,NIH,Crossover Assignment,Diagnostic,Adalimumab,Anti-TNF,Crohn's Disease
NCT96417196,Study of Adalimumab in Psoriasis,A Phase 1 Study of Adalimumab for the Treatment of Psoriasis,Observational,Phase 1,625,2020-03-25,2020-10-21,Completed,NIH,Crossover Assignment,Diagnostic,Adalimumab,Anti-TNF,Psoriasis
NCT44511828,Study of Adalimumab in Psoriasis,A Phase 2 Study of Adalimumab for the Treatment of Psoriasis,Observational,Phase 2,246,2023-09-11,2025-08-02,Suspended,NIH,Crossover Assignment,Treatment,Adalimumab,Anti-TNF,Psoriasis
NCT32085804,Study of Adalimumab in Psoriasis,A Phase 2 Study of Adalimumab for the Treatment of Psoriasis,Observational,Phase 2,950,2021-05-12,2023-01-15,Suspended,Other,Single Group Assignment,Prevention,Adalimumab,Anti-TNF,Psoriasis
NCT92889143,Study of Adalimumab in Psoriasis,A Phase 2 Study of Adalimumab for the Treatment of Psoriasis,Observational,Phase 2,925,2022-05-08,2024-04-24,Recruiting,NIH,Crossover Assignment,Supportive Care,Adalimumab,Anti-TNF,Psoriasis
NCT15815294,Study of Adalimumab in Psoriasis,A Phase 3 Study of Adalimumab for the Treatment of Psoriasis,Observational,Phase 3,247,2022-05-30,2022-07-23,Completed,NIH,Single Group Assignment,Treatment,Adalimumab,Anti-TNF,Psoriasis
NCT68719223,Study of Adalimumab in Psoriasis,A Phase 3 Study of Adalimumab for the Treatment of Psoriasis,Observational,Phase 3,346,2025-02-11,2026-10-29,Recruiting,Other,Parallel Assignment,Diagnostic,Adalimumab,Anti-TNF,Psoriasis
NCT30399032,Study of Adalimumab in Psoriasis,A Phase 3 Study of Adalimumab for the Treatment of Psoriasis,Interventional,Phase 3,749,2022-10-10,2024-07-25,Recruiting,Industry,Crossover Assignment,Prevention,Adalimumab,Anti-TNF,Psoriasis
NCT79831002,Study of Adalimumab in Psoriasis,A Phase 4 Study of Adalimumab for the Treatment of Psoriasis,Interventional,Phase 4,273,2024-07-26,2025-05-02,Suspended,Other,Single Group Assignment,Supportive Care,Adalimumab,Anti-TNF,Psoriasis
NCT49032232,Study of Adalimumab in Psoriasis,A Phase 4 Study of Adalimumab for the Treatment of Psoriasis,Interventional,Phase 4,29,2024-07-11,2025-12-08,Terminated,Industry,Single Group Assignment,Diagnostic,Adalimumab,Anti-TNF,Psoriasis
NCT55167681,Study of Infliximab in Rheumatoid Arthritis,A Phase 1 Study of Infliximab for the Treatment of Rheumatoid Arthritis,Observational,Phase 1,774,2021-07-31,2022-08-08,Terminated,NIH,Single Group Assignment,Supportive Care,Infliximab,Anti-TNF,Rheumatoid Arthritis
NCT16019324,Study of Infliximab in Rheumatoid Arthritis,A Phase 1 Study of Infliximab for the Treatment of Rheumatoid Arthritis,Observational,Phase 1,21,2020-04-11,2020-10-22,Suspended,Industry,Parallel Assignment,Prevention,Infliximab,Anti-TNF,Rheumatoid Arthritis
NCT31936985,Study of Infliximab in Rheumatoid Arthritis,A Phase 1 Study of Infliximab for the Treatment of Rheumatoid Arthritis,Interventional,Phase 1,304,2022-11-22,2023-09-13,Terminated,Other,Crossover Assignment,Treatment,Infliximab,Anti-TNF,Rheumatoid Arthritis
NCT75611145,Study of Infliximab in Rheumatoid Arthritis,A Phase 2 Study of Infliximab for the Treatment of Rheumatoid Arthritis,Observational,Phase 2,433,2021-03-31,2022-11-06,Terminated,NIH,Crossover Assignment,Prevention,Infliximab,Anti-TNF,Rheumatoid Arthritis
NCT99787561,Study of Infliximab in Rheumatoid Arthritis,A Phase 3 Study of Infliximab for the Treatment of Rheumatoid Arthritis,Observational,Phase 3,717,2022-02-21,2022-04-21,Suspended,Other,Single Group Assignment,Treatment,Infliximab,Anti-TNF,Rheumatoid Arthritis
NCT24208608,Study of Infliximab in Rheumatoid Arthritis,A Phase 3 Study of Infliximab for the Treatment of Rheumatoid Arthritis,Interventional,Phase 3,427,2024-11-08,2025-11-10,Suspended,NIH,Crossover Assignment,Prevention,Infliximab,Anti-TNF,Rheumatoid Arthritis
NCT43982576,Study of Infliximab in Rheumatoid Arthritis,A Phase 3 Study of Infliximab for the Treatment of Rheumatoid Arthritis,Interventional,Phase 3,633,2024-03-16,2025-12-31,Completed,Other,Crossover Assignment,Diagnostic,Infliximab,Anti-TNF,Rheumatoid Arthritis
NCT31344084,Study of Infliximab in Rheumatoid Arthritis,A Phase 4 Study of Infliximab for the Treatment of Rheumatoid Arthritis,Interventional,Phase 4,584,2022-10-11,2022-11-24,Completed,Other,Parallel Assignment,Treatment,Infliximab,Anti-TNF,Rheumatoid Arthritis
NCT15451654,Study of Infliximab in Rheumatoid Arthritis,A Phase 4 Study of Infliximab for the Treatment of Rheumatoid Arthritis,Observational,Phase 4,460,2021-08-11,2022-10-17,Terminated,NIH,Crossover Assignment,Supportive Care,Infliximab,Anti-TNF,Rheumatoid Arthritis
NCT90733242,Study of Infliximab in Rheumatoid Arthritis,A Phase 4 Study of Infliximab for the Treatment of Rheumatoid Arthritis,Interventional,Phase 4,275,2023-05-31,2024-07-16,Suspended,Other,Single Group Assignment,Supportive Care,Infliximab,Anti-TNF,Rheumatoid Arthritis
NCT31094512,Study of Infliximab in Crohn's Disease,A Phase 1 Study of Infliximab for the Treatment of Crohn's Disease,Observational,Phase 1,952,2020-05-21,2020-08-29,Terminated,Industry,Crossover Assignment,Treatment,Infliximab,Anti-TNF,Crohn's Disease
NCT82979804,Study of Infliximab in Crohn's Disease,A Phase 1 Study of Infliximab for the Treatment of Crohn's Disease,Interventional,Phase 1,677,2024-02-19,2024-03-23,Completed,Industry,Crossover Assignment,Treatment,Infliximab,Anti-TNF,Crohn's Disease
NCT30804216,Study of Infliximab in Crohn's Disease,A Phase 1 Study of Infliximab for the Treatment of Crohn's Disease,Observational,Phase 1,172,2021-01-17,2021-06-23,Recruiting,Other,Crossover Assignment,Supportive Care,Infliximab,Anti-TNF,Crohn's Disease
NCT47154172,Study of Infliximab in Crohn's Disease,A Phase 2 Study of Infliximab for the Treatment of Crohn's Disease,Interventional,Phase 2,673,2021-05-25,2023-04-11,Completed,Industry,Parallel Assignment,Diagnostic,Infliximab,Anti-TNF,Crohn's Disease
NCT17286189,Study of Infliximab in Crohn's Disease,A Phase 2 Study of Infliximab for the Treatment of Crohn's Disease,Interventional,Phase 2,432,2021-05-15,2021-07-31,Terminated,NIH,Single Group Assignment,Prevention,Infliximab,Anti-TNF,Crohn's Disease
NCT97360248,Study of Infliximab in Crohn's Disease,A Phase 2 Study of Infliximab for the Treatment of Crohn's Disease,Observational,Phase 2,242,2025-03-19,2027-01-03,Terminated,Industry,Single Group Assignment,Supportive Care,Infliximab,Anti-TNF,Crohn's Disease
NCT12891154,Study of Infliximab in Crohn's Disease,A Phase 3 Study of Infliximab for the Treatment of Crohn's Disease,Observational,Phase 3,887,2022-09-29,2023-08-14,Terminated,Other,Single Group Assignment,Supportive Care,Infliximab,Anti-TNF,Crohn's Disease
NCT17612082,Study of Infliximab in Crohn's Disease,A Phase 4 Study of Infliximab for the Treatment of Crohn's Disease,Interventional,Phase 4,121,2025-04-22,2027-02-11,Terminated,Industry,Parallel Assignment,Supportive Care,Infliximab,Anti-TNF,Crohn's Disease
NCT43370171,Study of Infliximab in Crohn's Disease,A Phase 4 Study of Infliximab for the Treatment of Crohn's Disease,Observational,Phase 4,886,2023-02-05,2023-10-31,Suspended,NIH,Parallel Assignment,Diagnostic,Infliximab,Anti-TNF,Crohn's Disease
NCT93835633,Study of Infliximab in Crohn's Disease,A Phase 4 Study of Infliximab for the Treatment of Crohn's Disease,Observational,Phase 4,450,2024-03-24,2024-09-11,Completed,Other,Single Group Assignment,Supportive Care,Infliximab,Anti-TNF,Crohn's Disease
NCT34886786,Study of Infliximab in Psoriasis,A Phase 1 Study of Infliximab for the Treatment of Psoriasis,Observational,Phase 1,32,2024-06-22,2024-11-15,Terminated,Other,Single Group Assignment,Supportive Care,Infliximab,Anti-TNF,Psoriasis
NCT12508045,Study of Infliximab in Psoriasis,A Phase 1 Study of Infliximab for the Treatment of Psoriasis,Observational,Phase 1,710,2022-06-30,2022-12-13,Recruiting,Other,Parallel Assignment,Prevention,Infliximab,Anti-TNF,Psoriasis
NCT59756976,Study of Infliximab in Psoriasis,A Phase 2 Study of Infliximab for the Treatment of Psoriasis,Interventional,Phase 2,396,2022-03-17,2023-10-23,Suspended,NIH,Crossover Assignment,Diagnostic,Infliximab,Anti-TNF,Psoriasis
NCT20102274,Study of Infliximab in Psoriasis,A Phase 2 Study of Infliximab for the Treatment of Psoriasis,Interventional,Phase 2,123,2024-12-28,2026-07-26,Recruiting,NIH,Parallel Assignment,Prevention,Infliximab,Anti-TNF,Psoriasis
NCT56010568,Study of Infliximab in Psoriasis,A Phase 2 Study of Infliximab for the Treatment of Psoriasis,Interventional,Phase 2,356,2022-12-15,2023-10-11,Completed,Industry,Crossover Assignment,Prevention,Infliximab,Anti-TNF,Psoriasis
NCT82942613,Study of Infliximab in Psoriasis,A Phase 3 Study of Infliximab for the Treatment of Psoriasis,Observational,Phase 3,896,2023-02-22,2023-07-15,Completed,Industry,Parallel Assignment,Supportive Care,Infliximab,Anti-TNF,Psoriasis
NCT23874360,Study of Infliximab in Psoriasis,A Phase 3 Study of Infliximab for the Treatment of Psoriasis,Interventional,Phase 3,932,2021-04-11,2023-04-02,Recruiting,Other,Crossover Assignment,Diagnostic,Infliximab,Anti-TNF,Psoriasis
NCT73100492,Study of Infliximab in Psoriasis,A Phase 3 Study of Infliximab for the Treatment of Psoriasis,Interventional,Phase 3,975,2020-03-04,2021-12-22,Recruiting,Other,Parallel Assignment,Prevention,Infliximab,Anti-TNF,Psoriasis
NCT11972949,Study of Infliximab in Psoriasis,A Phase 4 Study of Infliximab for the Treatment of Psoriasis,Interventional,Phase 4,485,2023-11-27,2025-08-05,Completed,NIH,Crossover Assignment,Supportive Care,Infliximab,Anti-TNF,Psoriasis
NCT80399181,Study of Certolizumab in Rheumatoid Arthritis,A Phase 1 Study of Certolizumab for the Treatment of Rheumatoid Arthritis,Interventional,Phase 1,753,2024-05-06,2024-09-06,Terminated,NIH,Parallel Assignment,Treatment,Certolizumab,Anti-TNF,Rheumatoid Arthritis
NCT81449223,Study of Certolizumab in Rheumatoid Arthritis,A Phase 1 Study of Certolizumab for the Treatment of Rheumatoid Arthritis,Observational,Phase 1,505,2022-08-20,2024-02-06,Terminated,Other,Single Group Assignment,Prevention,Certolizumab,Anti-TNF,Rheumatoid Arthritis
NCT95177158,Study of Certolizumab in Rheumatoid Arthritis,A Phase 1 Study of Certolizumab for the Treatment of Rheumatoid Arthritis,Observational,Phase 1,706,2022-05-04,2023-12-08,Suspended,Other,Parallel Assignment,Prevention,Certolizumab,Anti-TNF,Rheumatoid Arthritis
NCT15990835,Study of Certolizumab in Rheumatoid Arthritis,A Phase 2 Study of Certolizumab for the Treatment of Rheumatoid Arthritis,Interventional,Phase 2,970,2024-05-25,2026-02-20,Recruiting,Other,Parallel Assignment,Prevention,Certolizumab,Anti-TNF,Rheumatoid Arthritis
NCT62484067,Study of Certolizumab in Rheumatoid Arthritis,A Phase 3 Study of Certolizumab for the Treatment of Rheumatoid Arthritis,Interventional,Phase 3,266,2022-03-19,2023-12-23,Recruiting,NIH,Parallel Assignment,Treatment,Certolizumab,Anti-TNF,Rheumatoid Arthritis
NCT76321648,Study of Certolizumab in Rheumatoid Arthritis,A Phase 3 Study of Certolizumab for the Treatment of Rheumatoid Arthritis,Interventional,Phase 3,961,2021-03-11,2021-07-20,Terminated,Industry,Crossover Assignment,Supportive Care,Certolizumab,Anti-TNF,Rheumatoid Arthritis
NCT11808985,Study of Certolizumab in Rheumatoid Arthritis,A Phase 4 Study of Certolizumab for the Treatment of Rheumatoid Arthritis,Interventional,Phase 4,888,2022-09-11,2022-12-14,Terminated,Industry,Crossover Assignment,Diagnostic,Certolizumab,Anti-TNF,Rheumatoid Arthritis
NCT46815158,Study of Certolizumab in Rheumatoid Arthritis,A Phase 4 Study of Certolizumab for the Treatment of Rheumatoid Arthritis,Observational,Phase 4,31,2023-02-03,2023-06-06,Recruiting,NIH,Parallel Assignment,Diagnostic,Certolizumab,Anti-TNF,Rheumatoid Arthritis
NCT35993705,Study of Certolizumab in Crohn's Disease,A Phase 1 Study of Certolizumab for the Treatment of Crohn's Disease,Observational,Phase 1,801,2022-11-08,2023-08-13,Completed,NIH,Parallel Assignment,Diagnostic,Certolizumab,Anti-TNF,Crohn's Disease
NCT85373679,Study of Certolizumab in Crohn's Disease,A Phase 2 Study of Certolizumab for the Treatment of Crohn's Disease,Interventional,Phase 2,537,2024-03-05,2025-06-20,Recruiting,Other,Crossover Assignment,Supportive Care,Certolizumab,Anti-TNF,Crohn's Disease
NCT41165618,Study of Certolizumab in Crohn's Disease,A Phase 2 Study of Certolizumab for the Treatment of Crohn's Disease,Observational,Phase 2,783,2021-08-11,2023-01-04,Recruiting,NIH,Crossover Assignment,Diagnostic,Certolizumab,Anti-TNF,Crohn's Disease
NCT74965919,Study of Certolizumab in Crohn's Disease,A Phase 2 Study of Certolizumab for the Treatment of Crohn's Disease,Observational,Phase 2,64,2024-06-02,2025-06-28,Completed,Industry,Crossover Assignment,Diagnostic,Certolizumab,Anti-TNF,Crohn's Disease
NCT70065580,Study of Certolizumab in Crohn's Disease,A Phase 3 Study of Certolizumab for the Treatment of Crohn's Disease,Interventional,Phase 3,979,2022-04-09,2023-09-19,Suspended,Other,Single Group Assignment,Treatment,Certolizumab,Anti-TNF,Crohn's Disease
NCT93831616,Study of Certolizumab in Crohn's Disease,A Phase 3 Study of Certolizumab for the Treatment of Crohn's Disease,Interventional,Phase 3,305,2022-07-04,2023-04-28,Recruiting,NIH,Crossover Assignment,Prevention,Certolizumab,Anti-TNF,Crohn's Disease
NCT71567453,Study of Certolizumab in Crohn's Disease,A Phase 3 Study of Certolizumab for the Treatment of Crohn's Disease,Interventional,Phase 3,800,2022-05-21,2023-08-25,Suspended,Industry,Single Group Assignment,Supportive Care,Certolizumab,Anti-TNF,Crohn's Disease
NCT42977990,Study of Certolizumab in Crohn's Disease,A Phase 4 Study of Certolizumab for the Treatment of Crohn's Disease,Observational,Phase 4,764,2023-01-09,2023-08-07,Completed,NIH,Single Group Assignment,Diagnostic,Certolizumab,Anti-TNF,Crohn's Disease
NCT29107906,Study of Certolizumab in Psoriasis,A Phase 1 Study of Certolizumab for the Treatment of Psoriasis,Interventional,Phase 1,593,2023-08-22,2024-07-06,Recruiting,Industry,Parallel Assignment,Treatment,Certolizumab,Anti-TNF,Psoriasis
NCT89978301,Study of Certolizumab in Psoriasis,A Phase 2 Study of Certolizumab for the Treatment of Psoriasis,Observational,Phase 2,53,2023-08-19,2024-10-01,Suspended,Other,Single Group Assignment,Treatment,Certolizumab,Anti-TNF,Psoriasis
NCT63389468,Study of Certolizumab in Psoriasis,A Phase 3 Study of Certolizumab for the Treatment of Psoriasis,Observational,Phase 3,146,2025-02-06,2025-12-08,Terminated,NIH,Parallel Assignment,Treatment,Certolizumab,Anti-TNF,Psoriasis
NCT94256173,Study of Certolizumab in Psoriasis,A Phase 4 Study of Certolizumab for the Treatment of Psoriasis,Observational,Phase 4,982,2021-07-09,2022-02-03,Recruiting,Other,Parallel Assignment,Prevention,Certolizumab,Anti-TNF,Psoriasis
